# 2025年12月9日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 无同步顺铂的托瑞帕利单抗为基础的鼻咽癌治疗——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359350)
**期刊：** JAMA
**PMID：** 41359350
**DOI：** 10.1001/jama.2025.20100

### 第一部分 原文与翻译

**英文原标题：** Toripalimab-Based Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本篇文章属于作者针对‘无同步顺铂的托瑞帕利单抗为基础的鼻咽癌治疗’相关研究的回复信。尽管未提供摘要，但从标题可推测内容主要针对同行质疑或讨论，澄清研究设计或结果的解释。该文可能强调免疫治疗在鼻咽癌治疗策略中的独立应用价值，同时指出无需同步化疗的潜在可行性。创新点在于拓展免疫治疗独立应用的思路，但缺乏进一步实验或临床数据支持。

---

## 2. 无同步顺铂的托瑞帕利单抗联合治疗鼻咽癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359328)
**期刊：** JAMA
**PMID：** 41359328
**DOI：** 10.1001/jama.2025.20102

### 第一部分 原文与翻译

**英文原标题：** Toripalimab-Based Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦于在鼻咽癌治疗中采用不含同步顺铂的托瑞帕利单抗为基础的方案，可能旨在评估其疗效与安全性之间的平衡。此方向反映出在降低化疗毒性同时维持或提升免疫治疗疗效的探索趋势。虽然目前缺乏具体研究摘要，但该主题暗示了免疫治疗在鼻咽癌治疗策略中的潜在独立地位。未来仍需进一步临床证据以验证其可行性和长期效果。

---

## 3. 针对鼻咽癌的无顺铂同期使用的特瑞普利单抗联合治疗方案

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359312)
**期刊：** JAMA
**PMID：** 41359312
**DOI：** 10.1001/jama.2025.20104

### 第一部分 原文与翻译

**英文原标题：** Toripalimab-Based Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究发表于《JAMA》，聚焦于在鼻咽癌治疗中应用特瑞普利单抗联合方案但不合并顺铂的临床策略。此类治疗可能旨在探讨能否在降低顺铂相关毒性的同时维持或提高疗效。尽管缺乏摘要，标题暗示研究可能基于免疫治疗优化与化疗减负的思路。未来应关注其疗效、安全性比较及潜在的免疫机制探索。

---

## 4. 推进CAR T细胞治疗：基于循证医学的肿瘤嵌合抗原受体T细胞治疗临床试验设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359310)
**期刊：** JAMA
**PMID：** 41359310
**DOI：** 10.1001/jama.2025.21721

### 第一部分 原文与翻译

**英文原标题：** Advancing CAR T-Cell Therapy: Evidence-Based Trial Design for Chimeric Antigen Receptor T-Cell Therapy in Oncology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究旨在探讨如何通过循证医学方法优化CAR T细胞治疗在肿瘤学领域的临床试验设计。虽然具体方法和结果尚未披露，但从标题可见文章意在推动CAR T疗法从经验性应用走向科学化、标准化评估的阶段。这种设计理念有助于提升试验的可重复性与疗效验证的可靠性。其创新点在于将循证思维引入细胞治疗研究，局限性则可能在于实施复杂度与试验成本较高。

---

## 5. IGVF目录——从遗传变异到功能的全景框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359121)
**期刊：** Nucleic acids research
**PMID：** 41359121
**DOI：** 10.1093/nar/gkaf1341

### 第一部分 原文与翻译

**英文原标题：** The IGVF catalog-from genetic variation to function.

> **英文摘要：**
> Genomic variation between individuals is essential for understanding how differences in the genome sequence affect molecular and cellular processes. The Impact of Genomic Variation on Function (IGVF) Consortium aims to uncover the relationships among genomic variation, genome function, and phenotypes by combining experimental techniques, such as single-cell mapping and genomic perturbation assays, with computational approaches such as machine learning-based predictive modeling. The IGVF Data and Administrative Coordinating Centers collect, analyze, and disseminate data and results from across the consortium through an open-source platform called the IGVF Catalog. This resource includes, but is not limited to, data on the effects of coding variants on protein abundance and function, noncoding variants on enhancer activity (measured by MPRA or predicted computationally), and associations between variants and quantitative traits. All data are organized within a graph database comprising over 50 types of data collections with nearly 3 billion nodes and over 7.5 billion edges. The Catalog offers public API endpoints (https://api.catalogkg.igvf.org/) and a user-friendly interface for exploring, querying, and visualizing the data at https://catalog.igvf.org. We expect that this open-access platform will support the broader scientific community to advance our understanding of how genomic variation influences biology and disease.

> **中文摘要：**
> 个体间的基因组变异对于理解基因组序列差异如何影响分子和细胞过程至关重要。基因变异对功能的影响（IGVF）联盟旨在通过结合实验技术（如单细胞图谱构建和基因组扰动实验）与计算方法（如基于机器学习的预测建模），揭示基因组变异、基因组功能与表型之间的关系。IGVF数据与管理协调中心通过一个名为IGVF目录的开源平台，收集、分析并传播整个联盟的数据和研究成果。该资源包括但不限于：编码变异对蛋白丰度和功能的影响、非编码变异对增强子活性的作用（通过MPRA测定或计算预测），以及变异与定量性状之间的关联。所有数据均组织在一个图数据库中，包含超过50种数据集，总计约30亿个节点和超过75亿条边。该目录提供公共API端点（https://api.catalogkg.igvf.org/）以及用户友好的界面，可在https://catalog.igvf.org上进行数据探索、查询与可视化。我们期望这一开放获取平台能够支持更广泛的科学群体，推动对基因组变异如何影响生物学与疾病机制的理解。

### 第二部分 AI 大师评价

本文系统介绍了IGVF联盟构建的开放数据资源——IGVF目录，旨在整合实验与计算手段，解析基因变异对功能及表型的影响。其创新在于以大规模图数据库形式整合海量多类型数据，并提供公共API与可视化工具，极大提高了数据可访问性与可扩展性。文章突出了跨尺度整合与开放协作的理念，为基因组功能研究奠定了基础。然而，该平台的后续挑战仍包括持续的数据标准化、功能注释质量以及跨实验系统之间的互操作性。

---

## 6. 用于p47缺陷型慢性肉芽肿病的引导编辑治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41358590)
**期刊：** The New England journal of medicine
**PMID：** 41358590
**DOI：** 10.1056/NEJMoa2509807

### 第一部分 原文与翻译

**英文原标题：** Prime Editing for p47-Deficient Chronic Granulomatous Disease.

> **英文摘要：**
> Chronic granulomatous disease (CGD) is a severe monogenic immunodeficiency caused by damaging variants in genes required for microbicidal NADPH oxidase activity. Autosomal recessive p47-deficient CGD (p47-CGD) is predominantly caused by a two-nucleotide deletion in exon 2 (delGT) of . We developed PM359, an autologous CD34+ hematopoietic stem-cell therapy in which prime editing is used to correct delGT. Two participants received PM359 after myeloid conditioning with busulfan: neutrophils and platelets engrafted promptly in both patients. Adverse events were consistent with myeloid conditioning with busulfan. NADPH oxidase activity was observed in neutrophils within 1 month and was maintained for 6 months and 4 months as of the last follow-up visit in Participants 1 and 2, respectively. These results support further investigation of prime editing of CD34+ cells to treat p47-CGD. (Funded by Prime Medicine; ClinicalTrials.gov number, NCT06559176.).

> **中文摘要：**
> 慢性肉芽肿病（CGD）是一种由损伤性基因变异引起的严重单基因免疫缺陷疾病，这些基因对于杀菌性NADPH氧化酶的活性至关重要。常染色体隐性p47缺陷型CGD（p47-CGD）的主要致病原因是位于第2外显子的两个核苷酸缺失（delGT）。我们开发了PM359，这是一种自体CD34+造血干细胞治疗，其中采用引导编辑技术纠正delGT突变。两名受试者在使用布司他芬进行髓系预处理后接受了PM359治疗：两位患者的中性粒细胞和血小板均迅速植入。与布司他芬髓系预处理相一致的不良事件被观察到。在中性粒细胞中于1个月内检测到NADPH氧化酶活性，并在截至最终随访时的第1和第2位参与者中分别维持了6个月和4个月。这些结果支持进一步研究通过对CD34+细胞进行引导编辑以治疗p47-CGD。（由Prime Medicine资助；ClinicalTrials.gov登记号：NCT06559176。）

### 第二部分 AI 大师评价

本研究旨在利用引导编辑技术修复p47缺陷型慢性肉芽肿病患者的致病性delGT突变，开发出PM359自体造血干细胞疗法。早期临床结果显示，该疗法可实现造血细胞快速植入并恢复中性粒细胞的NADPH氧化酶活性，疗效持续达数月。研究创新性地验证了引导编辑在原代造血干细胞中的安全性与功能可行性。虽然仅涉及两名受试者且随访期有限，但结果为基因编辑治疗单基因免疫缺陷提供了重要的临床探索依据。

---

## 7. 利用Talquetamab和Teclistamab对髓外性骨髓瘤的双重靶向治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41358582)
**期刊：** The New England journal of medicine
**PMID：** 41358582
**DOI：** 10.1056/NEJMoa2514752

### 第一部分 原文与翻译

**英文原标题：** Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

> **英文摘要：**
> BACKGROUND: Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising efficacy with dual-antigen targeting of myeloma with talquetamab (anti-G protein-coupled receptor family C group 5 member D) plus teclistamab (anti-B-cell maturation antigen) in patients with triple-class-exposed relapsed or refractory multiple myeloma, including those with true extramedullary myeloma.
> 
> METHODS: In this phase 2 study, we investigated talquetamab plus teclistamab exclusively in patients with drug-resistant, true extramedullary myeloma. The primary end point was overall response, evaluated with the use of functional imaging. Secondary end points included the duration of response, progression-free survival, overall survival, and safety.
> 
> RESULTS: A total of 90 patients were enrolled in the study and received treatment (median follow-up, 12.6 months). A response occurred in 79% of the patients (95% confidence interval [CI], 69 to 87). Among the patients with a response, the percentage with a response duration of at least 12 months was 64% (95% CI, 48 to 76). At 12 months, progression-free survival was 61% (95% CI, 50 to 71), and overall survival was 74% (95% CI, 63 to 83). Common adverse events of any grade included oral symptoms, such as dysgeusia, dry mouth, and dysphagia (in 87% of the patients); cytokine release syndrome (in 78%); and nonrash skin effects (in 69%). Grade 3 or 4 adverse events (most commonly hematologic events) occurred in 76% of the patients; 31% had grade 3 or 4 infection. A nonfatal adverse event led to discontinuation of one or both agents in 6% of the patients. Among 10 deaths that occurred during follow-up, 5 were due to infection and 5 were considered to be related to the study treatment.
> 
> CONCLUSIONS: Most patients with drug-resistant, true extramedullary myeloma had a response with talquetamab plus teclistamab. The incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy. (Funded by Johnson & Johnson; RedirecTT-1 ClinicalTrials.gov number, NCT04586426.).

> **中文摘要：**
> 背景：具有与骨髓不连续的浆细胞瘤（真正的髓外性骨髓瘤）的患者，其疾病进展或复发风险较高。RedirecTT-1研究的第一阶段显示，在暴露于三类药物且复发或难治的多发性骨髓瘤患者（包括真正髓外性骨髓瘤患者）中，采用Talquetamab（抗G蛋白偶联受体家族C组5成员D抗体）联合Teclistamab（抗B细胞成熟抗原抗体）进行双靶抗原治疗具有令人鼓舞的疗效。
> 
> 方法：在这项第二阶段研究中，我们专门在药物耐受的真正髓外性骨髓瘤患者中研究Talquetamab联合Teclistamab的疗效。主要终点为总体应答率，通过功能性影像评估。次要终点包括应答持续时间、无进展生存期、总生存期以及安全性。
> 
> 结果：共纳入90例患者并接受治疗（中位随访12.6个月）。应答率为79%（95%置信区间[CI]，69至87）。在获得应答的患者中，应答持续时间至少12个月的比例为64%（95% CI，48至76）。在12个月时，无进展生存率为61%（95% CI，50至71），总生存率为74%（95% CI，63至83）。常见的不分级不良事件包括口腔症状（如味觉障碍、口干和吞咽困难，占87%）、细胞因子释放综合征（78%）及非皮疹性皮肤反应（69%）。3或4级不良事件（最常见为血液学事件）发生于76%的患者中；31%的患者发生了3或4级感染。6%的患者因非致命不良事件而停用一种或两种药物。在随访期间发生的10例死亡中，5例因感染导致，5例被认为与研究治疗相关。
> 
> 结论：多数药物耐受的真正髓外性骨髓瘤患者对Talquetamab联合Teclistamab产生应答。3级及以上不良事件的发生率较高，与各单药治疗时的既往观察一致。（由强生公司资助；RedirecTT-1研究，ClinicalTrials.gov编号NCT04586426。）

### 第二部分 AI 大师评价

本研究针对药物耐受的真正髓外性骨髓瘤，评估了Talquetamab与Teclistamab的双靶点治疗策略。在功能影像评估下，该组合方案显示出79%的总体应答率和较长的应答持续时间，疗效显著。尽管3级及以上不良事件较为常见，但总体安全性与单药研究结果相符。研究为难治性髓外性骨髓瘤提供了新的治疗思路，但样本量有限和高毒性仍需进一步验证。

---

## 8. ACSL5 在谷氨酰胺缺乏条件下调控结直肠癌细胞的葡萄糖代谢与化疗敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355704)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355704
**DOI：** 10.1002/advs.202510801

### 第一部分 原文与翻译

**英文原标题：** ACSL5 Regulates Glucose Metabolism and Chemotherapy Sensitivity in Colorectal Cancer Cells under Glutamine Deficiency.

> **英文摘要：**
> Glutamine metabolism is crucial for sustaining tumor cell viability and growth, broadly promoting prospects for the therapeutic targeting of glutamine dependence. However, further research is needed to address key translational issues, particularly to better understand the adaptive survival responses employed by cancer cells in overcoming nutrient deficiency. Long-chain acyl-CoA synthetase 5 (ACSL5) is found to be upregulated under glutamine deprivation, acting to sustain tumor cell viability by enhancing both glycolytic flux and oxidative phosphorylation. ACSL5 operates within a p53 regulatory loop: p53 transcriptionally upregulates ACSL5, while ACSL5 competes with MIB1 to stabilize MDM2, suppressing p53 expression. Mechanistically, ACSL5 relieves p53-mediated inhibition of PGAM1 to drive glycolysis, while its mitochondrial localization promotes IDH2 activation to accelerate the TCA cycle. Nonetheless, these metabolic increases also generate reactive oxygen species (ROS), inducing DNA damage and significantly enhancing colorectal cancer cell sensitivity to oxaliplatin. The latter provides an explanation as to why colorectal tumors with high ACSL5 expression display preferentially improved patient outcomes from chemotherapy. Collectively, the findings reveal a new pathway for non-genetic chemotherapy resistance mechanisms, deepen the understanding of metabolic reprogramming in tumor cells, and offer potential therapeutic targets for future treatment strategies.

> **中文摘要：**
> 谷氨酰胺代谢对于维持肿瘤细胞的存活与生长至关重要，这一过程广泛推动了针对谷氨酰胺依赖性的治疗靶向研究前景。然而，仍需进一步研究来解决关键的转化性问题，特别是更好地理解癌细胞在应对营养缺乏时所采用的适应性生存反应。研究发现，在谷氨酰胺剥夺条件下，长链酰基辅酶A合成酶5（ACSL5）表达上调，通过增强糖酵解通量和氧化磷酸化来维持肿瘤细胞的活力。ACSL5 作用于一个由 p53 调控的反馈环路中：p53 转录性上调 ACSL5，而 ACSL5 通过与 MIB1 竞争稳定 MDM2，从而抑制 p53 的表达。在机制上，ACSL5 解除 p53 介导的对 PGAM1 的抑制以推动糖酵解，同时其线粒体定位促进 IDH2 活化，加速三羧酸循环。然而，这些代谢增强也导致活性氧（ROS）的生成，引发 DNA 损伤并显著提高结直肠癌细胞对奥沙利铂的敏感性。这一结果解释了高 ACSL5 表达的结直肠肿瘤患者在化疗中预后较好的原因。总体而言，这些发现揭示了一种新的非遗传性化疗耐药机制通路，加深了对肿瘤细胞代谢重编程的理解，并为未来的治疗策略提供了潜在靶点。

### 第二部分 AI 大师评价

该研究旨在阐明 ACSL5 在谷氨酰胺缺乏条件下对结直肠癌细胞代谢及化疗敏感性的调控机制。通过揭示其在 p53 调控网络中的作用，研究指出 ACSL5 可通过增强糖酵解和氧化磷酸化来维持细胞存活，同时提高化疗药物奥沙利铂的敏感性。该成果创新性地连接了代谢重编程与化疗反应，为非遗传性耐药机制提供了新的解释。其潜在的临床意义在于为结直肠癌药物敏感性预测及代谢靶向治疗提供理论依据，但仍需更多体内验证与临床转化研究。

---

## 9. YAP 的相分离介导 AJUBA 超增强子激活以促进乳腺癌中的异常有丝分裂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355615)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355615
**DOI：** 10.1002/advs.202409341

### 第一部分 原文与翻译

**英文原标题：** Phase-Separation of YAP Mediates AJUBA Super Enhancer Activation to Promote Aberrant Mitosis in Breast Cancer.

> **英文摘要：**
> Aberrant mitosis is a hallmark of cancer, which drives chromosomal instability, gene dysregulation, tumor heterogeneity, immune evasion, and therapy resistance. In this study, it is observed that dysregulation of YAP signaling can cause supernumerary centrosome clustering, thereby triggering pseudo-bipolar/multipolar diversion during anaphase in breast cancer. Mechanistically, the YAP can accumulate and hyperactivate the super-enhancer of the spindle assembly checkpoint, AJUBA, in a phase-separation-dependent manner, thus leading to aberrant mitosis. These findings reveal a crucial biological role of YAP-mediated super enhancer activation and provide new insights into aneuploidy formation in breast cancer.

> **中文摘要：**
> 异常的有丝分裂是癌症的标志之一，它驱动染色体不稳定、基因调控紊乱、肿瘤异质性、免疫逃逸以及治疗耐受。在本研究中，观察到 YAP 信号通路的失调可导致过多中心体的聚集，从而在乳腺癌细胞中触发后期的伪双极或多极分裂。机制上，YAP 能以相分离依赖的方式积聚并高活化纺锤体装配检查点的超增强子 AJUBA，从而导致异常的有丝分裂。该研究结果揭示了 YAP 介导超增强子激活的关键生物学作用，并为乳腺癌中非整倍体形成提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明 YAP 相分离在乳腺癌有丝分裂异常中的分子机制。通过揭示 YAP 依赖相分离激活 AJUBA 超增强子的过程，研究揭示了染色体不稳定与细胞分裂失调之间的新联系。这一发现深化了对 YAP 生物学功能的理解，并为探索乳腺癌非整倍体形成提供了潜在靶点。其创新性在于将相分离理论与超增强子调控机制相结合，但仍需在临床样本和多模型验证方面进一步拓展。

---

## 10. GLUL赋予血管周围癌相关成纤维细胞促血管生成能力以促进胶质瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355614)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355614
**DOI：** 10.1002/advs.202513184

### 第一部分 原文与翻译

**英文原标题：** GLUL Confers Perivascular Cancer-Associated Fibroblasts With Pro-Angiogenic Capacity to Promote Glioma Progression.

> **英文摘要：**
> Glioblastoma (GBM) is a malignant brain tumor characterized by profound angiogenic activity and immunosuppressive features. A burgeoning body of research has focused on elucidating the functional effects of stromal cells within the tumor microenvironment (TME) and developing stroma-targeted therapeutic strategies. Notably, cancer-associated fibroblasts (CAFs), essential stromal components of the TME, have garnered significant attention for their functional orchestration in glioma progression. The proteomic landscape of human primary CAFs from GBM samples has revealed the dynamic remodeling of differential protein expression in the TME, but the functional role of glutamate-ammonia ligase (GLUL) as a novel CAF target remains elusive. This study confirms that GLUL knockdown profoundly abrogated the architectural intricacy inherent to CAF-supported vasculature in vitro and in vivo. Additionally, CAF-specific GLUL knockdown attenuates tumor growth and extends median survival in a humanized orthotopic glioma model. Furthermore, GLUL-driven activation of PI3K/AKT signaling as the central regulator of CAF-mediated vascular niche formation is delineated in glioma progression. This study highlights that targeting GLUL in CAFs is a novel stroma-focused therapeutic paradigm for GBM by disrupting pro-angiogenic signaling. Collectively, these findings elucidate key aspects of CAF biology and their regulatory functions in tumor progression, underscoring the therapeutic potential of targeting CAFs in GBM.

> **中文摘要：**
> 胶质母细胞瘤（GBM）是一种以显著的血管生成活性和免疫抑制特征为特点的恶性脑肿瘤。不断增长的研究致力于阐明肿瘤微环境（TME）中基质细胞的功能作用，并开发针对基质的治疗策略。值得注意的是，癌相关成纤维细胞（CAFs）作为TME中至关重要的基质成分，因其在胶质瘤进展中的功能调控作用而受到极大关注。来自GBM样本的人原代CAFs的蛋白质组学图谱揭示了TME中差异蛋白表达的动态重塑，但谷氨酰胺-氨连接酶（GLUL）作为一种新的CAF靶点的功能作用仍不清楚。本研究证实，GLUL的敲低显著削弱了CAFs支持的血管结构在体内外的复杂性。此外，特异性敲低CAFs中的GLUL可减缓肿瘤生长，并延长人源化原位胶质瘤模型中的中位生存期。进一步地，本研究阐明了GLUL驱动的PI3K/AKT信号通路激活是CAFs介导的血管生态位形成的核心调控因素，在胶质瘤进展中发挥关键作用。本研究强调，通过破坏促血管生成信号，靶向CAFs中的GLUL为GBM提供了一种新型的以基质为中心的治疗范式。总体而言，这些发现阐明了CAFs生物学及其在肿瘤进展中的调控功能的关键方面，突出了在GBM中靶向CAFs的治疗潜力。

### 第二部分 AI 大师评价

该研究聚焦于GLUL在癌相关成纤维细胞（CAFs）中的功能，揭示其如何通过PI3K/AKT信号通路促进胶质瘤的血管生成与进展。通过体内外实验证明，GLUL敲低可显著抑制CAFs支持的血管结构形成，并延缓肿瘤生长。研究提出了以CAFs代谢酶为靶点的全新治疗思路，拓展了针对肿瘤基质调控的治疗策略。其创新性在于揭示了GLUL-CAFs轴在血管生态位形成中的关键作用，但仍需进一步探讨临床转化和安全性问题。

---

## 11. 利用最少临床肿瘤样本在5天内实现快速微流控药物敏感性检测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355609)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355609
**DOI：** 10.1002/advs.202511065

### 第一部分 原文与翻译

**英文原标题：** Rapid Microfluidic Drug Sensitivity Testing Within 5 Days Using Minimal Clinical Tumor Samples.

> **英文摘要：**
> Rapid screening of personalized drugs based on patients' primary cell samples can provide precise and timely treatment guidance for clinical oncology patients. However, this goal faces great challenges due to the scarce clinical samples and large sample consumption, and long experimental time required by current drug screening methods. Here, a rapid, high-throughput microfluidic drug sensitivity testing system capable of accomplishing single and combination drug screening of multiple antitumor drugs in 5 days is established with minimal amounts of clinical primary tumor samples, avoiding the need for cell pre-expansion and preserving the tumor heterogeneity. An airflow-impacting approach is developed to fabricate nanoliter-scale microcavity arrays with ultra-smooth microcavity surfaces, with which rapid formation and 3D culture of tumor cell spheroids from small numbers of cell samples, as well as the subsequent high-throughput drug sensitivity testing can be achieved within 5 days. This applies the system in rapid drug sensitivity testing on primary samples from 21 clinical breast cancer patients to quantify the responses of patient-derived cells to chemotherapy and endocrine drugs under both the mono-drug and combinational-drug treatment modes.

> **中文摘要：**
> 基于患者原代细胞样本的个体化药物快速筛选可为临床肿瘤患者提供精准且及时的治疗指导。然而，由于临床样本稀缺、样本消耗量大以及现有药物筛选方法所需实验时间较长，实现这一目标面临巨大挑战。本研究建立了一种快速、高通量的微流控药物敏感性检测系统，只需极少量的临床原发性肿瘤样本，即可在5天内完成多种抗肿瘤药物的单药及联合用药筛选，无需细胞预扩增，并可保留肿瘤异质性。研究开发了一种气流撞击方法，用于制备纳升级微腔阵列，这些微腔具有超光滑的内表面，借此实现了从少量细胞样本中快速形成和三维培养肿瘤细胞球体，并在5天内完成后续的高通量药物敏感性检测。该系统应用于来自21例临床乳腺癌患者的原发样本，量化了患者来源细胞对化疗药物和内分泌药物在单药及联合治疗模式下的响应。

### 第二部分 AI 大师评价

该研究旨在解决临床肿瘤药物敏感性检测存在样本量需求大和耗时长的问题。团队建立了一种基于微流控技术的快速高通量检测平台，可利用极少量肿瘤样本在5天内实现单药及联合药物的筛选。该方法通过气流撞击制备超光滑纳升级微腔阵列，显著提升了三维细胞球体的形成效率和检测速度。研究在乳腺癌患者样本中的验证展示了其实用潜力和保持肿瘤异质性的优势。局限性可能包括在不同肿瘤类型间的适用性及系统标准化程度仍需进一步验证。

---

## 12. 通过T细胞糖工程调控免疫–肿瘤互作：一种增强肿瘤免疫治疗的通用非遗传策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355605)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355605
**DOI：** 10.1002/advs.202505387

### 第一部分 原文与翻译

**英文原标题：** T Cell Glycoengineering to Modulate Immune-Tumor Crosstalk: A Universal Non-Genetic Strategy for Enhanced Tumor Immunotherapy.

> **英文摘要：**
> Gene-engineered T cell therapies, particularly chimeric antigen receptor (CAR)-T cells, have demonstrated remarkable clinical success. However, concerns regarding insertional mutagenesis and other risks associated with genetic modification remain. Here, a non-genetic strategy is presented for T cell engineering using glycopolymer modification. It develops glycopolymer-modified T (G-T) cells based on antigen-specific T cells by integrating metabolic glycoengineering and click chemistry, yielding cells that retain T cell functionality while significantly enhancing tumor enrichment. The polyvalent glycopolymer-receptor interactions significantly improved the binding affinity of G-T cells to various glucose transporter 1 (GLUT1)-overexpressing tumor cells, resulting in increased cytotoxicity compared to unmodified T cells. In the tumor microenvironment, G-T cells engaged in stronger immune crosstalk with dendritic cells (DCs), upregulating interferon-gamma (IFN-γ) and interleukin-12 (IL-12) secretion and amplifying the anti-tumor immune response. Notably, despite the lower specificity of glycan-receptor interactions compared to antigen-antibody binding, the findings reveal an unexpected advantage: the "less restrictive" nature of glycan-receptor recognition enhances both tumor and immune cell interactions, triggering a potent immune cascade. This study establishes a universal, non-genetic T cell engineering strategy with broad applicability, offering a new perspective for tumor immunotherapy by merging biomedical polymer materials with immune modulation.

> **中文摘要：**
> 基因工程化的T细胞治疗，尤其是嵌合抗原受体（CAR）T细胞，已在临床上取得了显著成功。然而，关于插入性突变及其他与基因修饰相关的风险仍令人担忧。本研究提出了一种利用糖聚合物修饰的非遗传性T细胞工程策略。通过整合代谢性糖工程与点击化学，在抗原特异性T细胞基础上制备了糖聚合物修饰的T（G-T）细胞，使其保留T细胞功能的同时显著提高了肿瘤富集能力。多价糖聚合物–受体相互作用显著增强了G-T细胞与多种葡萄糖转运蛋白1（GLUT1）高表达肿瘤细胞的结合亲和力，与未修饰的T细胞相比，展现出更高的细胞毒性。在肿瘤微环境中，G-T细胞与树突状细胞（DC）之间产生了更强的免疫互作，促进了干扰素-γ（IFN-γ）和白介素-12（IL-12）的分泌，从而放大抗肿瘤免疫反应。值得注意的是，尽管糖链–受体相互作用的特异性低于抗原–抗体结合，但研究结果揭示了一个意外优势：糖链–受体识别的“较少限制性”特征增强了肿瘤细胞与免疫细胞的双向互作，激发了强有力的免疫级联反应。本研究确立了一种具有广泛适用性的通用非遗传性T细胞工程策略，通过融合生物医用聚合物材料与免疫调控，为肿瘤免疫治疗提供了新的研究视角。

### 第二部分 AI 大师评价

本研究旨在开发一种不依赖基因修饰的T细胞工程化新方法，通过糖聚合物修饰提升T细胞的肿瘤靶向性与免疫调控功能。研究以代谢性糖工程结合点击化学实现T细胞表面糖结构的精准修饰，从而增强其与GLUT1高表达肿瘤细胞的结合和杀伤能力。值得关注的是，该策略在优化T细胞–树突状细胞互作及促进关键细胞因子表达方面表现突出。该研究在实现安全性与效能平衡上具有创新意义，但仍需验证其体内长期稳定性与潜在脱靶风险。

---

## 13. 靶向内皮细胞中的NRP1促进瘢痕血管正常化并预防纤维性瘢痕形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355602)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355602
**DOI：** 10.1002/advs.202510545

### 第一部分 原文与翻译

**英文原标题：** Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring.

> **英文摘要：**
> Current clinical treatments for skin scars primarily reduce vascular density in situ. But, outcomes remain unsatisfactory due to limited understanding of scar vascular structure, endothelial cell (EC) heterogeneity, and functional changes. Through dermatoscopy, scanning electron microscopy, and immunofluorescence staining, our study revealed substantial vascular remodeling in scars, including increased neovascularization density, branching complexity, and incomplete vascular wall coverage. Single-cell sequencing constructed an EC atlas of scar patients, identifying upregulated ATP synthesis, decomposition, and oxidative phosphorylation in scar ECs-characteristics resembling tumor vasculature. Notably, a subset of ECs with high neuropilin-1 (NRP1) expression exhibited mesenchymal characteristics. In vitro experiments demonstrated that NRP1 knockdown blocked the transforming growth factor-beta (TGF-β)/SMAD family member 2 (SMAD2) signaling pathway and mitigated endothelial-to-mesenchymal transition (EndMT). Importantly, NRP1 inhibition reduced EndMT, restored normal vascular function and structure, and prevented scar formation in mice. Based on these findings, a functional hydrogel spray was developed using an NRP1-targeting peptide, effectively preventing scar formation by promoting vascular normalization.

> **中文摘要：**
> 目前针对皮肤瘢痕的临床治疗主要是降低局部的血管密度。然而，由于对瘢痕血管结构、内皮细胞（EC）异质性及功能变化的理解有限，治疗效果仍不理想。通过皮肤镜、扫描电镜及免疫荧光染色，本研究揭示了瘢痕组织中显著的血管重塑现象，包括新生血管密度增高、分支复杂度增加及血管壁覆盖不完全。单细胞测序构建了来自瘢痕患者的内皮细胞图谱，发现瘢痕内皮细胞中ATP合成、分解及氧化磷酸化过程上调——呈现出类似肿瘤血管的特征。值得注意的是，一部分高表达神经纤毛蛋白-1（NRP1）的内皮细胞表现出间充质特征。体外实验表明，下调NRP1可阻断转化生长因子β（TGF-β）/SMAD家族成员2（SMAD2）信号通路，并减轻内皮-间充质转化（EndMT）。重要的是，抑制NRP1可降低EndMT、恢复血管的正常功能与结构，并防止小鼠瘢痕形成。基于这些发现，研究者开发了一种含NRP1靶向肽的功能性水凝胶喷雾，通过促进血管正常化有效预防瘢痕形成。

### 第二部分 AI 大师评价

本研究旨在通过靶向内皮细胞中的NRP1，改善瘢痕组织的病理性血管结构，从而防止纤维性瘢痕生成。研究方法涵盖多模态显微分析、单细胞测序及体内外功能实验，揭示了瘢痕内皮细胞代谢活跃且具肿瘤样特征的分子图谱。研究发现NRP1是介导TGF-β/SMAD2通路和诱导EndMT的关键节点，抑制其功能可恢复血管正常化并阻止瘢痕形成。创新性在于提出了血管正常化调控作为瘢痕防治的新策略，并开发出NRP1靶向水凝胶喷雾。但其在临床应用中的长期安全性及人群差异仍需进一步验证。

---

## 14. 富含干细胞记忆的病毒特异性T细胞针对CMV和EBV的过继转移的安全性与有效性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355594)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355594
**DOI：** 10.1002/advs.202510288

### 第一部分 原文与翻译

**英文原标题：** Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV.

> **英文摘要：**
> Adoptive immunotherapy with third-party virus-specific T lymphocytes (VSTs) is effective against refractory viral infections. However, its long-term efficacy and persistence must be enhanced. T memory stem cells (TSCMs) with superior self-renewal and multilineage differentiation potential may enhance VSTs durability, although their antiviral capacity is underexplored. Cytomegalovirus (CMV)-and Epstein-Barr virus (EBV)-specific T cells are enriched with CD8⁺ TSCM through cytokine and peptide stimulation. Comprehensive preclinical evaluations show that purified TSCM-VSTs exhibit reduced exhaustion, enhanced expansion, and stronger antiviral activity than central or effector memory VSTs (TCM or TEM). Transcriptomic and epigenetic analyses show significant enrichment of the MAPK and Wnt signaling pathways, consistent with stem-like characteristics. In a murine model, CD8⁺ TSCM VSTs provide more effective protection against Raji-pp65 tumors than TCM or TEM VSTs. In a phase I clinical trial, 10 patients with refractory CMV or EBV infections post-transplant who received third-party, off-the-shelf TSCM-enriched VSTs show a 100% overall response rate and 70% complete response, with persistence up to 12 weeks and no severe adverse events. These findings support TSCM-enriched VSTs as a potent, scalable antiviral immunotherapy and highlight TSCM proportion as a critical determinant of VSTs efficacy.

> **中文摘要：**
> 采用第三方来源的病毒特异性T淋巴细胞（VSTs）进行过继免疫治疗对难治性病毒感染具有疗效。然而，其长期疗效和持续性仍需提高。具有卓越自我更新与多谱系分化潜能的T记忆干细胞（TSCMs）可能增强VSTs的持久性，尽管其抗病毒能力尚未得到充分研究。研究者通过细胞因子与肽刺激使细胞巨细胞病毒（CMV）和EB病毒（EBV）特异性T细胞富集CD8⁺ TSCM。系统的临床前评估表明，纯化的TSCM-VSTs相比中央记忆或效应记忆VSTs（TCM或TEM）表现出更低的衰竭、更强的扩增能力以及更强的抗病毒活性。转录组和表观遗传学分析显示，其在MAPK和Wnt信号通路上有显著富集，与干样特性一致。在小鼠模型中，CD8⁺ TSCM VSTs较TCM或TEM VSTs对Raji-pp65肿瘤提供更有效的保护作用。在一项I期临床试验中，10例移植后难治性CMV或EBV感染患者接受第三方、即用型TSCM富集VSTs治疗后，总体反应率达100%，完全反应率为70%，持久时间可达12周，且未观察到严重不良事件。这些结果支持TSCM富集VSTs作为一种高效、可扩展的抗病毒免疫治疗，并强调TSCM比例是VSTs疗效的重要决定因素。

### 第二部分 AI 大师评价

本研究旨在通过富集T记忆干细胞（TSCM）提升病毒特异性T细胞（VSTs）治疗CMV和EBV感染的持久性与疗效。研究结合体外功能评估、转录与表观遗传分析以及动物实验，证实TSCM-VSTs具有更强的增殖潜能、干样特征和抗病毒效应。I期临床试验显示治疗安全且反应率高，验证了该策略的临床可行性。创新点在于引入干细胞样T细胞以优化现有VST疗法，但其长期免疫记忆维持与大规模制造仍需进一步探索。

---

## 15. 二甲双胍在来源于POLG患者的脑类器官中恢复线粒体功能和神经发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355579)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355579
**DOI：** 10.1002/advs.202417721

### 第一部分 原文与翻译

**英文原标题：** Metformin Restores Mitochondrial Function and Neurogenesis in POLG Patient-Derived Brain Organoids.

> **英文摘要：**
> Mitochondrial dysfunction and impaired neurogenesis are central to mitochondrial DNA polymerase (POLG)-related disorders, yet therapeutic options remain limited. Here, patient-derived induced pluripotent stem cell (iPSC)-based cortical organoids are used to model POLG-associated neurodegeneration and assess the therapeutic potential of metformin. Single-cell RNA-seq reveals distinct vulnerabilities in dopaminergic, glutamatergic, and GABAergic neuronal subtypes, with dopaminergic neurons exhibiting the most severe loss and mitochondrial transcriptomic deficits. Metformin treatment (250 µm, 2 months) significantly restores neuronal identity, subtype-specific gene expression, and mitochondrial function. Functional assays demonstrate improved mitochondrial membrane potential (TMRE), increased mitochondrial mass (MTG, MTDR), and reduced oxidative stress (MitoSOX, BAX/cleaved caspase 3). Notably, mitochondrial DNA (mtDNA) copy number and the expression of mitochondrial replisome proteins (POLG, POLG2) are upregulated, indicating enhanced mitochondrial genome maintenance. Calcium measurement confirms improved neuronal excitability. Untargeted metabolomics further reveals metformin-induced metabolic reprogramming, including enrichment of the tricarboxylic acid (TCA) cycle, amino acid metabolism, and redox-related pathways. Together, these findings demonstrate that metformin enhances mitochondrial integrity and neural function across multiple neuronal subtypes and offer mechanistic insights into its potential as a treatment for POLG-related disorders.

> **中文摘要：**
> 线粒体功能障碍与神经发生受损是线粒体DNA聚合酶（POLG）相关疾病的核心特征，但现有治疗选择仍然有限。本研究利用来源于患者的诱导多能干细胞（iPSC）构建的皮质类器官，模拟POLG相关神经退行性变并评估二甲双胍的治疗潜力。单细胞RNA测序揭示多巴胺能、谷氨酸能和GABA能神经元亚型中存在不同的易损性，其中多巴胺能神经元表现出最严重的丢失和线粒体转录组缺陷。二甲双胍处理（250 µm，持续2个月）显著恢复了神经元身份、亚型特异性基因表达及线粒体功能。功能检测显示线粒体膜电位（TMRE）改善，线粒体质量（MTG、MTDR）增加，氧化应激（MitoSOX、BAX/切割型半胱天冬酶3）降低。值得注意的是，线粒体DNA（mtDNA）拷贝数及线粒体复制体复合物蛋白（POLG、POLG2）的表达水平均上调，提示线粒体基因组维护得到增强。钙离子检测证实神经元兴奋性改善。非靶向代谢组学进一步揭示二甲双胍诱导的代谢重编程，包括三羧酸（TCA）循环、氨基酸代谢及氧化还原相关通路的富集。总体而言，这些发现表明二甲双胍可增强多种神经元亚型的线粒体完整性与神经功能，为其作为POLG相关疾病潜在治疗提供了机制性见解。

### 第二部分 AI 大师评价

本研究以患者来源的iPSC皮质类器官模型探讨二甲双胍治疗POLG相关神经退行性疾病的机制。通过单细胞转录组学和多组学分析，揭示二甲双胍可改善线粒体功能、促进神经发生并缓解氧化应激。研究创新之处在于将代谢药物应用于遗传性线粒体疾病模型，并整合功能和分子层面的验证。尽管仍需体内研究和临床验证，但结果为POLG相关病变的代谢干预提供了重要依据。

---

## 16. 由IgG桥接诱导的SARS-CoV-2刺突协同聚集支撑了低亲和力抗体的强效中和作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355083)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355083
**DOI：** 10.1002/advs.202517192

### 第一部分 原文与翻译

**英文原标题：** IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody.

> **英文摘要：**
> Mechanistic studies of viral neutralization typically prioritize high-affinity antibodies, relegating low-affinity binders to the sidelines. P5‑1C8, a Class 1 SARS-CoV-2 antibody that exemplifies this underexplored "low‑affinity yet high‑potency" phenotype is reported, retaining strong neutralization of Omicron JN.1 despite markedly weakened trimer binding (K = 225 nM; IC = 0.06 nM). Structural and biophysical analyses reveal that P5-1C8 engages WT and BA.1 spikes through canonical intra-spike bivalency, but with JN.1 it induces aggregation. Using virion-like nanoparticles displaying multiple spikes, it is shown that IgG remains bound with no detectable dissociation and triggers pronounced aggregation. Coarse-grained molecular dynamics delineate the stepwise pathway in which weak IgG-spike contacts seed aggregation via transient inter-spike bridging. Together, these findings establish the first mechanistic framework demonstrating how weak-binding antibodies can nonetheless achieve potent neutralization through higher-order aggregation, thereby expanding the conceptual landscape of antibody function and opening new directions for antibody evaluation and design.

> **中文摘要：**
> 病毒中和的机制性研究通常优先关注高亲和力抗体，而将低亲和力结合物置于次要位置。本研究报道了一种代表这种“低亲和却高效价”表型的SARS-CoV-2 1类抗体P5‑1C8，即使其对三聚体的结合显著减弱（K = 225 nM；IC = 0.06 nM），仍能保持对Omicron JN.1的强效中和作用。结构和生物物理分析表明，P5-1C8通过典型的刺突内双价结合与野生型和BA.1刺突相互作用，但在JN.1中则诱导刺突聚集。利用显示多刺突的类病毒纳米颗粒实验发现，IgG可保持结合而无可检测的解离，并触发显著聚集。粗粒度分子动力学模拟描绘了一个逐步过程，即弱IgG-刺突接触通过瞬时的刺突间桥接作用播种聚集。总体而言，这些发现建立了首个机制框架，揭示弱结合抗体如何仍能通过高阶聚集实现强效中和，从而拓展了抗体功能的概念边界，并为抗体评估与设计开辟了新方向。

### 第二部分 AI 大师评价

该研究旨在揭示低亲和力抗体如何实现对SARS-CoV-2的高效中和。作者通过结构、生物物理及分子动力学方法，发现抗体P5-1C8能通过IgG桥接触发刺突的协同聚集，从而维持中和活性。研究首次建立了弱结合抗体通过高阶聚集实现强效中和的机制模型，拓宽了抗体功能的理解。其创新性在于揭示低亲和力抗体的潜在优势，但仍需进一步研究其在体内环境中的稳定性与免疫反应影响。

---

## 17. 核心岩藻糖化抑制依赖SMURF1的CD47降解以促进肿瘤免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355073)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41355073
**DOI：** 10.1002/advs.202516863

### 第一部分 原文与翻译

**英文原标题：** Core Fucosylation Represses SMURF1-Dependent Degradation of CD47 to Promote Tumor Immune Evasion.

> **英文摘要：**
> Glycosylation, the covalent attachment of glycans to proteins, lipids, and RNAs, is fundamental in regulating diverse biological processes. Glycosylation patterns are aberrantly altered in the tumor microenvironment and closely associated with tumor immune escape. However, the molecular mechanisms by which glycosylation regulates tumor immune escape are poorly understood. We show that Cluster of Differentiation 47 (CD47), an innate immune checkpoint protein, is highly modified with core fucosylated N-linked glycans. Core fucosylation of CD47 mediated by fucosyltransferase 8 (FUT8) at asparagine 111 (N111) reduces CD47 ubiquitination and degradation. Blockade of N111 glycosylation represses CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, elimination of N111 glycosylation promotes the infiltration of CD103 dendritic cells (DCs), leading to the increased recruitment of natural killer (NK) cells and inhibition of tumor growth in a murine hepatocellular carcinoma (HCC) model. Combined treatment with core fucosylation inhibitors and an anti-CD47 antibody synergistically promotes therapeutic efficacy in the HCC model. Finally, FUT8 levels in human HCC specimens are positively correlated with CD47 expressions and negatively correlated with the infiltration of CD103 DC and NK cells. Collectively, this study reveals a mechanism underlying CD47 upregulation in tumor cells and highlights the potential of targeting the FUT8-SMURF1-CD47 axis as a therapeutic strategy to improve anti-tumor immune responses.

> **中文摘要：**
> 糖基化是糖链与蛋白质、脂类及RNA共价结合的过程，在调控多种生物学过程方面具有基础性作用。肿瘤微环境中的糖基化模式常发生异常改变，并与肿瘤免疫逃逸密切相关。然而，糖基化调控肿瘤免疫逃逸的分子机制仍缺乏深入理解。我们发现分化簇47（CD47），一种固有免疫检查点蛋白，具有高度核心岩藻糖化的N-连接糖链。由岩藻糖基转移酶8（FUT8）介导的CD47在天冬酰胺111（N111）处的核心岩藻糖化可减少CD47的泛素化与降解。阻断N111位点的糖基化会抑制CD47的表达，并促进巨噬细胞对肿瘤细胞的吞噬。此外，去除N111糖基化促进了CD103树突状细胞（DC）的浸润，从而增强自然杀伤（NK）细胞的募集，并在小鼠肝细胞癌（HCC）模型中抑制肿瘤生长。将核心岩藻糖化抑制剂与抗CD47抗体联合使用可在HCC模型中协同增强治疗效果。最终，在人HCC样本中，FUT8水平与CD47表达呈正相关，而与CD103 DC和NK细胞的浸润呈负相关。综上所述，本研究揭示了肿瘤细胞CD47上调的潜在机制，并强调靶向FUT8-SMURF1-CD47通路以改善抗肿瘤免疫反应的治疗潜力。

### 第二部分 AI 大师评价

本研究明确揭示了核心岩藻糖化修饰通过抑制SMURF1介导的CD47降解而促进肿瘤免疫逃逸的机制。研究采用分子、细胞及动物模型相结合的方法，系统阐明了FUT8介导的CD47糖基化对肝癌免疫微环境的作用，并验证了核心岩藻糖化抑制剂与抗CD47抗体联合治疗的协同效应。该工作在机制解析和治疗拓展上具有创新性，为开发靶向FUT8-SMURF1-CD47轴的抗肿瘤免疫策略提供了新思路。但仍需在临床样本及不同肿瘤类型中进一步验证其普适性与安全性。

---

## 18. PACIFIC-5：针对不可切除Ⅲ期非小细胞肺癌且在同步或序贯放化疗后未进展患者的巩固治疗Durvalumab的Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354932)
**期刊：** Journal of hematology & oncology
**PMID：** 41354932
**DOI：** 10.1186/s13045-025-01768-1

### 第一部分 原文与翻译

**英文原标题：** PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.

> **英文摘要：**
> BACKGROUND: Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many patients receive sequential CRT (sCRT). The PACIFIC-5 trial aimed to evaluate the efficacy and safety of consolidation durvalumab for unresectable stage III NSCLC following no progression on cCRT or sCRT.
> 
> METHODS: This randomised, double-blind, placebo-controlled, phase III trial enrolled patients aged ≥ 18 years with unresectable stage III NSCLC, regardless of PD-L1 expression or sensitising EGFR or ALK aberrations, without disease progression after cCRT or sCRT. Patients were randomised (2:1) to durvalumab 1500 mg or placebo intravenously every 4 weeks (stratified by tumour PD-L1 expression and prior treatment) until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was progression-free survival (PFS) by blinded independent central review in the modified intention-to-treat population (mITT). Secondary endpoints included overall survival (OS) in the mITT and safety. The safety analysis set include patients who received at least one dose of study treatment.
> 
> RESULTS: Of 407 patients randomised to receive durvalumab (n = 272) or placebo (n = 135), 405 received at least one dose of durvalumab (n = 271) or placebo (n = 134). The mITT comprised 381 patients randomised to durvalumab (n = 252) or placebo (n = 129). Durvalumab showed statistically significant improvement in PFS versus placebo in the mITT (median [95% confidence interval {CI}], 14.0 [10.9-18.0] vs. 6.5 [5.4-13.8] months; hazard ratio [95% CI], 0.75 [0.58-0.99]; p = 0.038). There was a trend toward improved OS with durvalumab versus placebo in the mITT (median [95% CI], 38.3 [28.9-42.8] vs. 32.5 [20.6-40.4] months; hazard ratio [95% CI], 0.87 [0.66-1.17]; p = 0.346 [interim analysis]). Among the safety analysis set, maximum grade 3 or 4 adverse events of any cause occurred in 26.9% (73/271) and 23.9% (32/134) and 1.5% (4/271) and 0% (0/134) had treatment-related adverse events leading to death for durvalumab and placebo, respectively.
> 
> CONCLUSIONS: PACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.
> 
> TRIAL REGISTRATION: NCT03706690.

> **中文摘要：**
> 背景：在同步放化疗（cCRT）后未出现疾病进展的不可切除Ⅲ期非小细胞肺癌（NSCLC）患者中，巩固治疗用Durvalumab已成为标准治疗方案。然而，在临床实践中，许多患者接受的是序贯放化疗（sCRT）。PACIFIC-5试验旨在评估在cCRT或sCRT后未进展的不可切除Ⅲ期NSCLC患者接受巩固性Durvalumab治疗的疗效与安全性。
> 
> 方法：这项随机、双盲、安慰剂对照的Ⅲ期临床试验纳入年龄≥18岁的不可切除Ⅲ期NSCLC患者，不论PD-L1表达状态或是否存在敏感性EGFR或ALK突变，只要在cCRT或sCRT后未出现疾病进展即可入组。患者按2:1比例随机分配至Durvalumab 1500 mg或安慰剂组，每4周静脉滴注一次，并按肿瘤PD-L1表达及既往治疗分层，直至疾病进展、无法耐受的毒性或撤回同意为止。主要终点为经盲法独立中心评估的修正意向性治疗（mITT）人群的无进展生存期（PFS）。次要终点包括mITT人群的总生存期（OS）及安全性。安全性分析集包括接受至少一剂研究药物的患者。
> 
> 结果：407名患者被随机分配至Durvalumab（n=272）或安慰剂（n=135）组，其中405人（Durvalumab组271例，安慰剂组134例）实际接受了至少一剂治疗。mITT人群包括Durvalumab组252例与安慰剂组129例。结果显示，在mITT人群中，Durvalumab较安慰剂显著改善了PFS（中位数[95%置信区间{CI}]：14.0 [10.9–18.0]个月 vs. 6.5 [5.4–13.8]个月；风险比[95% CI]：0.75 [0.58–0.99]；p=0.038）。Durvalumab在OS方面较安慰剂呈现改善趋势（中位数[95% CI]：38.3 [28.9–42.8]个月 vs. 32.5 [20.6–40.4]个月；风险比[95% CI]：0.87 [0.66–1.17]；p=0.346［期中分析］）。在安全性分析集中，任意原因导致的3或4级不良事件发生率分别为26.9%（73/271）和23.9%（32/134）；与治疗相关的致死性不良事件分别见于1.5%（4/271）与0%（0/134）。
> 
> 结论：PACIFIC-5试验达到了其主要终点，即在cCRT或sCRT后Durvalumab显著延长PFS。总生存期的随访仍在进行中。
> 
> 试验注册号：NCT03706690。

### 第二部分 AI 大师评价

PACIFIC-5研究验证了Durvalumab作为不可切除Ⅲ期NSCLC同步或序贯放化疗后的巩固治疗在延长无进展生存期方面的确切获益。这项设计严谨的Ⅲ期随机双盲研究首次同时纳入了cCRT与sCRT人群，增强了其真实临床相关性。尽管总生存期尚需进一步随访确认，但结果显示Durvalumab在不同放化疗序列后均具一致疗效和可接受安全性。研究为拓展Durvalumab的适用范围提供了新的循证依据。

---

## 19. 溶血磷脂酰乙醇胺18:1通过稳定SIRT6重新编程脂质代谢以驱动透明细胞肾细胞癌。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354870)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41354870
**DOI：** 10.1038/s41392-025-02496-1

### 第一部分 原文与翻译

**英文原标题：** Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism.

> **英文摘要：**
> Clear cell renal cell carcinoma (ccRCC) is characterized by profound lipid metabolic dysregulation, yet the mechanisms linking peritumoral adipose tissue (PAT)-derived lipid metabolites to tumor aggressiveness remain poorly defined. Here, we identified lysophosphatidylethanolamine 18:1 (LPE18:1), a lipid metabolite enriched in PAT and the arterial blood of ccRCC patients, as a critical driver of tumor growth and lipid deposition. Through multiomics analyses and functional studies, we demonstrated that LPE18:1 upregulates F-actin-capping protein subunit alpha-1 (CAPZA1), which recruits ubiquitin-specific peptidase 48 (USP48) to stabilize the NAD-dependent protein deacetylase sirtuin-6 (SIRT6) by inhibiting its proteasomal degradation. Increased SIRT6 epigenetically promotes acetyl-CoA acetyltransferase 2 (ACAT2) expression, redirecting lipid metabolism toward free cholesterol accumulation-a hallmark of ccRCC aggressiveness. Clinically, CAPZA1 and SIRT6 levels correlate with advanced tumor stage and poor prognosis in ccRCC cohorts. Genetic or pharmacological inhibition of the CAPZA1/SIRT6 axis can reverse LPE18:1-induced lipid deposition and tumor progression in xenograft models. Notably, targeting this axis with the SIRT6 inhibitor OSS-128167 combined with CAPZA1 depletion significantly suppresses ccRCC cell growth. Our study reveals a PAT-derived lipid metabolite-fuelled signaling cascade that reprograms lipid metabolism in ccRCC, identifying CAPZA1/USP48/SIRT6 as actionable therapeutic targets for metabolic malignancies.

> **中文摘要：**
> 透明细胞型肾细胞癌（ccRCC）的特征是显著的脂质代谢失调，但肿瘤周围脂肪组织（PAT）来源的脂质代谢物与肿瘤侵袭性之间的机制仍缺乏明确解释。在本研究中，我们鉴定出一种在ccRCC患者的PAT及动脉血中富集的脂质代谢物——溶血磷脂酰乙醇胺18:1（LPE18:1），其作为肿瘤生长和脂质沉积的关键驱动因子。通过多组学分析和功能研究，我们发现LPE18:1可上调F-肌动蛋白封端蛋白α1亚基（CAPZA1），该蛋白招募特异性去泛素酶48（USP48），通过抑制NAD依赖型蛋白去乙酰化酶sirtuin-6（SIRT6）的蛋白酶体降解，从而稳定SIRT6。SIRT6水平升高从表观遗传层面上促进乙酰辅酶A乙酰转移酶2（ACAT2）的表达，使脂质代谢重新定向至游离胆固醇的积累——这是ccRCC侵袭性的标志。临床上，CAPZA1和SIRT6的表达水平与ccRCC患者的晚期肿瘤分期及不良预后显著相关。遗传或药理学地抑制CAPZA1/SIRT6通路可在异种移植模型中逆转LPE18:1诱导的脂质沉积与肿瘤进展。值得注意的是，使用SIRT6抑制剂OSS-128167并联合敲低CAPZA1显著抑制了ccRCC细胞的生长。本研究揭示了一条由PAT来源脂质代谢物驱动的信号级联途径，该途径在ccRCC中重塑脂质代谢，并确定CAPZA1/USP48/SIRT6轴为可操作的代谢性恶性肿瘤治疗靶点。

### 第二部分 AI 大师评价

本研究系统揭示了透明细胞肾癌中由肿瘤周围脂肪来源的LPE18:1介导的脂质代谢重编程机制。研究通过多组学整合与功能验证，明确了LPE18:1通过CAPZA1/USP48/SIRT6轴稳定位SIRT6并上调ACAT2，驱动游离胆固醇积累与肿瘤进展。其创新在于连接外源性脂质信号与表观遗传调控网络，为代谢性肿瘤治疗提供新靶点。局限性在于需进一步验证该通路在人群异质性及临床治疗中的普适性。

---

## 20. INSM1调控的一种神经祖细胞状态在人体干细胞模型中驱动胶质母细胞瘤的形成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354838)
**期刊：** Nature communications
**PMID：** 41354838
**DOI：** 10.1038/s41467-025-66371-x

### 第一部分 原文与翻译

**英文原标题：** INSM1 governs a neuronal progenitor state that drives glioblastoma in a human stem cell model.

> **英文摘要：**
> Glioblastoma is a lethal brain cancer marked by functional plasticity driven by tumor cell-intrinsic mutations and their interplay with developmental programs. To investigate how canonical glioblastoma mutations promote functional plasticity, we have developed an isogenic human neural stem cell (NSC) model of glioblastoma by sequential addition of TERT promoter, TP53, and PDGFRA point mutations. TP53 loss-of-function increases TERT expression during serial mutagenesis, but only triple mutant NSCs reliably form lethal brain tumors in vivo that recapitulate glioblastoma. Tumor cell evolution triggers stress-related metabolic changes and transitions toward a neuronal progenitor network driven by transcription factor INSM1. INSM1 is highly expressed in human glioblastoma tumors and, during cortical development, in intermediate progenitor cells, which give rise to neurons. Remarkably, INSM1 knockdown in triple mutant NSCs and primary glioblastoma cells disrupts oncogenic gene expression and function and inhibits the in vivo tumorigenicity of triple mutant NSCs, highlighting the functional importance of an intermediate progenitor cell-like cell state in glioblastoma pathogenesis.

> **中文摘要：**
> 胶质母细胞瘤是一种致命的脑部癌症，其特征是由肿瘤细胞内在突变及其与发育程序的相互作用所驱动的功能可塑性。为探究典型的胶质母细胞瘤突变如何促进功能可塑性，我们通过依次添加TERT启动子、TP53和PDGFRA点突变，建立了一个等基因型的人神经干细胞（NSC）胶质母细胞瘤模型。TP53功能缺失在连续诱变过程中可增加TERT的表达，但只有三重突变NSC能够在体内稳定形成致命的脑肿瘤，并重现胶质母细胞瘤特征。肿瘤细胞进化会引发与应激相关的代谢变化，并向由转录因子INSM1驱动的神经祖细胞网络转变。INSM1在人体胶质母细胞瘤肿瘤中以及大脑皮层发育过程中高表达，尤其存在于能生成神经元的中间祖细胞中。值得注意的是，敲低三重突变NSC及原代胶质母细胞瘤细胞中的INSM1，会破坏致癌基因的表达与功能，并抑制三重突变NSC的体内致瘤性，突显出类似中间祖细胞状态在胶质母细胞瘤发病机制中的功能重要性。

### 第二部分 AI 大师评价

本研究利用人源等基因型神经干细胞模型，系统重构了胶质母细胞瘤关键突变的演化过程，揭示了INSM1在驱动神经祖细胞样癌变状态中的核心作用。研究发现，只有TERT、TP53与PDGFRA三重突变可在体内生成可重复的致命脑瘤，并明确INSM1是这一转变网络的关键调控因子。INSM1的高表达与原始祖细胞特征和致瘤性密切相关，其敲低显著降低肿瘤形成能力。该研究创新性揭示了发育程式与肿瘤可塑性间的分子联系，但模型仍需进一步验证其在人类肿瘤进展中的普适性。

---

## 21. NSUN2介导的SOCS3 mRNA的m5C修饰调控膀胱癌中巨噬细胞极化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354740)
**期刊：** Cell death & disease
**PMID：** 41354740
**DOI：** 10.1038/s41419-025-08306-4

### 第一部分 原文与翻译

**英文原标题：** NSUN2-mediated m5C modification of SOCS3 mRNA modulates macrophage polarization in bladder cancer.

> **英文摘要：**
> Tumor-associated macrophages (TAMs) are pivotal in facilitating the progression of cancer cells. M1 and M2 are two polarization states of TAMs with opposite functions in tumor progression. While the regulatory role of N6-adenosine (m6A) methylation in macrophage polarization has been established, the function of 5-methylcytosine (m5C) remains unclear. The presence of M2 macrophages in bladder cancer and adjacent normal tissues was validated using fluorescence-activated cell sorting (FACS) and immunofluorescence (IF). The expression of reported m5C regulators (writers, readers, erasers) was screened in M2 macrophages to identify the most relevant regulators. Mechanistic insights into how m5C methylation regulates macrophage polarization were gained through RNA immunoprecipitation (RIP) and quantitative PCR. The FACS and IF results revealed that the main active state of the tumor microenvironment (TME) was the M2 subtype in bladder cancer. Next, NOP2/Sun RNA methyltransferase family member 2 (NSUN2) was identified as the most upregulated RNA m5C methylase in M2 via a qPCR assay. According to whole-transcriptome resequencing in si-NSUN2 RAW/THP-1 cells and GO analysis, SOCS3 was determined to be downstream of NSUN2. By methylating particular sites in SOCS3 mRNA, NSUN2 inhibits both the stability and nuclear export of SOCS3 mRNA, which subsequently activates the JAK2/STAT3 signaling pathway and then promotes macrophage polarization to the M2 phenotype while inhibiting M1 polarization. Additionally, this process involves the assistance and balance of the reader YBX1 and the eraser TET2. NSUN2 methylates SOCS3 mRNA to inhibit its stability and nuclear export, which consequently promotes macrophage polarization to M2.

> **中文摘要：**
> 肿瘤相关巨噬细胞（TAMs）在促进癌细胞进展中发挥关键作用。M1型和M2型是TAMs的两种极化状态，在肿瘤进展中具有相反的功能。虽然N6-腺苷（m6A）甲基化在巨噬细胞极化中的调控作用已被确定，但5-甲基胞嘧啶（m5C）的功能仍不清楚。研究通过荧光激活细胞分选（FACS）和免疫荧光（IF）验证了膀胱癌及其邻近正常组织中M2型巨噬细胞的存在。在M2巨噬细胞中筛查已报道的m5C调控因子（写入酶、读取蛋白、擦除酶）的表达，以确定最具相关性的调控分子。通过RNA免疫共沉淀（RIP）和定量PCR获得了m5C甲基化调控巨噬细胞极化的机制性见解。FACS和IF结果显示，膀胱癌肿瘤微环境（TME）的主要活跃状态为M2亚型。接下来，通过qPCR检测发现NOP2/Sun RNA甲基转移酶家族成员2（NSUN2）是M2中最上调的RNA m5C甲基化酶。根据si-NSUN2处理的RAW/THP-1细胞的全转录组重测序和GO分析，确定SOCS3是NSUN2的下游靶基因。NSUN2通过甲基化SOCS3 mRNA的特定位点，抑制其稳定性和核输出，从而激活JAK2/STAT3信号通路，促进巨噬细胞向M2表型极化，同时抑制M1极化。此外，该过程涉及读取蛋白YBX1和擦除酶TET2的协同作用和平衡。NSUN2通过甲基化SOCS3 mRNA抑制其稳定性和核输出，从而促进巨噬细胞向M2型极化。

### 第二部分 AI 大师评价

该研究以膀胱癌中的巨噬细胞极化为研究对象，揭示了NSUN2介导的SOCS3 mRNA的m5C修饰在调控M1/M2极化平衡中的关键作用。实验采用FACS、IF、RIP及转录组测序等多层次方法，系统阐明了NSUN2–SOCS3–JAK2/STAT3信号轴的分子机制。研究创新性地扩展了m5C表观转录修饰在免疫微环境调控中的认识，并强调了m5C调控与m6A不同的功能模式。其局限性在于尚需进一步验证该通路在体内免疫调节中的广泛性及潜在治疗价值。

---

## 22. SNRPA 上调促进线粒体功能并驱动去势抵抗性前列腺癌的侵袭性进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354732)
**期刊：** Cell death & disease
**PMID：** 41354732
**DOI：** 10.1038/s41419-025-08302-8

### 第一部分 原文与翻译

**英文原标题：** SNRPA upregulation promotes mitochondrial function and drives CRPC aggressiveness.

> **英文摘要：**
> Identifying novel molecular targets for castration-resistant prostate cancer (CRPC) is crucial. This study examines the expression and functional role of small nuclear ribonucleoprotein polypeptide A (SNRPA), a core component of the U1 snRNP complex, in CRPC. Bioinformatics analyses indicate a positive correlation between SNRPA overexpression and the aggressiveness of prostate cancer, with high levels linked to poor outcomes. Single-cell RNA data further shows increased SNRPA expression in prostate cancer cells. Expression of SNRPA is also elevated in both locally-treated CRPC tissues and various CRPC cells. Knockdown via shRNA or knockout using CRISPR/Cas9 significantly reduced cellular proliferation, migration, and invasion in CRPC cells, while inducing apoptosis. SNRPA depletion decreased complex I activity, ATP production, and mitochondrial membrane potential, increased reactive oxygen species levels, and downregulated NDUFB8/NDUFS9 expression. In contrast, SNRPA overexpression enhanced the aggressive phenotype of CRPC cells, boosting mitochondrial complex I activity and ATP generation, while upregulating NDUFB8/NDUFS9. In vivo studies using xenograft models further validated the therapeutic potential of targeting SNRPA. SNRPA knockdown significantly inhibited CRPC xenograft growth, reduced ATP levels, and altered redox balance, as evidenced by decreased glutathione/glutathione disulfide ratio and increased lipid peroxidation. These effects were accompanied by decreased proliferation, increased apoptosis and downregulated NDUFB8/NDUFS9. Our findings collectively suggest that SNRPA plays a crucial role in driving CRPC progression and represents a promising therapeutic target.

> **中文摘要：**
> 识别去势抵抗性前列腺癌（CRPC）的新型分子靶点至关重要。本研究探讨了小核核糖核蛋白多肽 A（SNRPA）——U1 小核核糖核蛋白复合体的核心组分——在 CRPC 中的表达及功能作用。生物信息学分析显示，SNRPA 的过表达与前列腺癌的侵袭性呈正相关，其高水平与较差的预后相关。单细胞 RNA 数据进一步表明，前列腺癌细胞中 SNRPA 表达升高。SNRPA 在接受局部治疗的 CRPC 组织及多种 CRPC 细胞中均表现出上调。通过 shRNA 敲低或 CRISPR/Cas9 敲除显著抑制了 CRPC 细胞的增殖、迁移和侵袭能力，同时诱导细胞凋亡。SNRPA 缺失降低了复合体 I 的活性、ATP 生成及线粒体膜电位，增加了活性氧水平，并下调 NDUFB8/NDUFS9 的表达。相反，SNRPA 过表达增强了 CRPC 细胞的侵袭性表型，提高了线粒体复合体 I 活性和 ATP 产生，并上调 NDUFB8/NDUFS9。在体内异种移植模型中进一步验证了靶向 SNRPA 的治疗潜力。SNRPA 敲低显著抑制了 CRPC 异种移植瘤的生长，降低了 ATP 水平，并改变了氧化还原平衡，表现为谷胱甘肽/谷胱甘肽二硫化物比下降和脂质过氧化增加。这些效应伴随着增殖下降、凋亡增强及 NDUFB8/NDUFS9 下调。我们的研究结果总体提示，SNRPA 在驱动 CRPC 进展中发挥关键作用，并代表一种有前景的治疗靶点。

### 第二部分 AI 大师评价

该研究通过系统分析揭示了 SNRPA 在去势抵抗性前列腺癌中促进线粒体功能及肿瘤侵袭性的核心作用。作者利用生物信息学、单细胞测序、体外功能实验及异种移植模型多层验证，证明 SNRPA 上调提升复合体 I 活性、ATP 生成并增强癌细胞存活与迁移能力。相反，其敲低导致氧化应激增强及能量代谢受损，从而诱导细胞凋亡。该研究创新性地将 SNRPA 与线粒体代谢重编程及 CRPC 的恶性进展联系起来，为靶向代谢/剪接因子的抗肿瘤策略提供了新的方向。但仍需进一步阐明其分子机制及临床可行性。

---

## 23. 既存与早期细胞免疫因素与对人类受控原发性 SARS-CoV-2 感染的功能性完全保护相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354730)
**期刊：** Nature communications
**PMID：** 41354730
**DOI：** 10.1038/s41467-025-67017-8

### 第一部分 原文与翻译

**英文原标题：** Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection.

> **英文摘要：**
> Identifying host factors that mediate protection against newly-emergent viruses is needed for improved pandemic preparedness. Here, we analysed pre- and early post-exposure immune factors associated with resisting SARS-CoV-2 infection after human challenge in seronegative individuals, using multiplex protein, cytometric and RNA sequencing approaches in the nasopharynx and circulation. Pre-existing cross-reactive antibodies correlate poorly with clinical outcome. Instead, protection is associated with heightened nasopharyngeal CCL13 levels locally produced by conventional dendritic cells and monocytes, along with cross-reactive T cells and less differentiated NK cells. Conditional independence network analysis implicates nasal CCL13 as the central node connected to pre-existing non-structural protein-specific T cells by CD1c DCs. In those who became infected, baseline cross-reactive T cell and less differentiated NK cell frequencies also correlate with shorter infection duration. Thus, pre-existing mucosal chemokine levels may promote rapid innate and innate-like responses that effectively block infection. ClinicalTrials.gov identifier NCT04865237.

> **中文摘要：**
> 为了提高大流行病防备能力，需要识别介导对新兴病毒防护的宿主因素。在此研究中，我们分析了在血清阴性个体接受人类挑战试验后，与抵抗 SARS-CoV-2 感染相关的既存和早期暴露后免疫因素，采用了多重蛋白分析、流式细胞术及鼻咽部和外周循环的 RNA 测序方法。既存的交叉反应性抗体与临床结局的相关性较弱。相反，保护与鼻咽部 CCL13 水平升高密切相关，而该化学因子由常规树突状细胞和单核细胞局部产生，并伴随有交叉反应性 T 细胞和分化程度较低的 NK 细胞。条件独立网络分析显示，鼻部 CCL13 是一个中心节点，通过 CD1c 树突状细胞与既存的非结构蛋白特异性 T 细胞相连接。在那些最终感染者中，基线时的交叉反应性 T 细胞和分化程度较低的 NK 细胞频率也与较短的感染持续时间有关。因此，既存的黏膜趋化因子水平可能可促进快速的先天及类先天免疫反应，从而有效阻断感染。ClinicalTrials.gov 登记号 NCT04865237。

### 第二部分 AI 大师评价

该研究通过人类受控感染模型，系统探索了既存及早期免疫因素与 SARS-CoV-2 感染防护之间的关联。作者整合了多组学检测（蛋白、流式、RNA测序），发现鼻咽部 CCL13 在防护性免疫网络中处于核心节点位置，连接特异性 T 细胞与树突状细胞功能。结果揭示了黏膜趋化因子在快速免疫应答中的关键作用，为理解自然防护机制及开发黏膜免疫干预策略提供重要依据。研究创新性强，但受样本规模与模型限制，仍需在更广泛人群中验证。

---

## 24. 治疗性6-硫代脱氧鸟苷通过诱导非产能停滞端粒酶复合物抑制癌细胞端粒延长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354720)
**期刊：** Nature communications
**PMID：** 41354720
**DOI：** 10.1038/s41467-025-66534-w

### 第一部分 原文与翻译

**英文原标题：** Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex.

> **英文摘要：**
> Most cancers upregulate the telomere lengthening enzyme telomerase to achieve unlimited cell division. How chemotherapeutic nucleoside 6-thio-2'-deoxyguanosine (6-thio-dG) targets telomerase to inhibit telomere maintenance in cancer cells and tumors was unclear. Here, we demonstrate that telomerase insertion of 6-thio-dGTP prevents synthesis of additional telomeric repeats but does not disrupt telomerase binding to telomeres. Specifically, 6-thio-dG inhibits telomere extension after telomerase translocates along its product DNA to reposition the template, inducing a non-productive complex rather than enzyme dissociation. Furthermore, we provide direct evidence that 6-thio-dG treatment inhibits telomere synthesis by telomerase in cancer cells. In agreement, telomerase-expressing cancer cells harboring critically short telomeres are more sensitive to 6-thio-dG and show a greater induction of telomere losses compared to cancer cells with long telomere reserves. Our studies reveal that telomere length and telomerase status determine 6-thio-dG sensitivity and uncover the molecular mechanism by which 6-thio-dG selectively inhibits telomerase synthesis of telomeric DNA.

> **中文摘要：**
> 大多数癌症通过上调端粒延长酶——端粒酶的活性，以实现无限制的细胞分裂。然而，化疗核苷6-硫代-2'-脱氧鸟苷(6-thio-dG)如何靶向端粒酶以抑制癌细胞和肿瘤中的端粒维持机制仍不清楚。在本研究中，我们证明了端粒酶将6-thio-dGTP插入端粒DNA后，会阻止额外端粒重复序列的合成，但并不破坏端粒酶与端粒的结合。具体而言，6-thio-dG在端粒酶沿其合成的DNA产物转位以重新定位模板后，抑制端粒延伸，并诱导形成一个非产能复合物，而不是导致酶的解离。此外，我们直接证实6-thio-dG处理可抑制癌细胞中端粒酶的端粒合成。与此一致的是，表达端粒酶且具有临界短端粒的癌细胞对6-thio-dG更为敏感，并表现出相比于长端粒癌细胞更显著的端粒丢失。我们的研究揭示了端粒长度和端粒酶状态决定6-thio-dG敏感性，并阐明6-thio-dG选择性抑制端粒酶合成端粒DNA的分子机制。

### 第二部分 AI 大师评价

该研究聚焦于化疗核苷6-thio-dG在抑制癌细胞端粒延长中的作用机制。作者通过分子水平实验揭示，该化合物并非通过破坏端粒酶结合，而是诱导非产能停滞复合物来阻断端粒延伸，从而直接抑制端粒合成。研究还发现，端粒较短且端粒酶阳性的癌细胞对6-thio-dG更敏感，提示端粒长度与端粒酶状态决定药物敏感性。该工作深入解析了6-thio-dG选择性靶向端粒酶的分子基础，为开发新型抗癌疗法提供了重要的机制学依据。

---

## 25. PLK1或WEE1抑制靶向BRCA1/2野生型高级别浆液性卵巢癌的同源重组修复能力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354716)
**期刊：** Cell death & disease
**PMID：** 41354716
**DOI：** 10.1038/s41419-025-08324-2

### 第一部分 原文与翻译

**英文原标题：** PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer.

> **英文摘要：**
> High-grade serous ovarian cancer (HGSOC) is a poor prognostic disease, especially in BRCA1/2 wild-type (BRCA-WT) patients with homologous recombination (HR) proficiency. These patients often show limited response to both platinum-based chemotherapy and PARP inhibitors. HR and non-homologous end joining (NHEJ) are the two major DNA double-strand break (DSB) repair pathways. HR is a precise repair mechanism for DSBs but is limited to S and G2 phases. In contrast, NHEJ functions more broadly throughout the cell cycle, including G1. We investigated whether inhibiting the G2/M checkpoint kinases PLK1 or WEE1 individually could disrupt mitotic control and expose therapeutic vulnerabilities in BRCA-WT/HR-proficient HGSOC cells. We evaluated cell cycle-targeted strategies to overcome HR-proficient chemoresistance using either volasertib (a selective PLK1 inhibitor) or adavosertib (a potent WEE1 inhibitor) in BRCA-WT/HR-proficient and BRCA-mutant/HR-deficient HGSOC models. Both agents induced DNA damage, impaired HR repair (reduced RAD51 foci), and triggered mitotic catastrophe-a form of cell death caused by defective mitosis and unresolved DNA damage-in BRCA-WT cells. Volasertib caused polyploidy and abnormal spindle formation, indicating mitotic slippage and cytokinesis failure, whereas adavosertib abrogated the G2/M checkpoint, forcing premature mitotic entry. In contrast, BRCA-mutant cells were resistant to either volasertib or adavosertib, consistent with sustained and functional NHEJ activity. This resistance was restored by the pharmacological or genetic inhibition of DNA-PKcs (DNA-dependent protein kinase, catalytic subunit), a prominent component of NHEJ. Functional and xenograft models confirmed selective vulnerability of BRCA-WT tumors to either PLK1 or WEE1 inhibition. Our work highlights a mechanistic framework linking cell cycle checkpoint inhibition to DNA repair pathway selectivity, providing a rationale for targeting mitotic regulators in HR-proficient ovarian cancer-a subgroup with high clinical unmet need.

> **中文摘要：**
> 高级别浆液性卵巢癌（HGSOC）是一种预后较差的疾病，尤其是在具备同源重组（HR）修复能力的BRCA1/2野生型（BRCA-WT）患者中。这类患者对以铂类为基础的化疗和PARP抑制剂的反应通常有限。HR和非同源末端连接（NHEJ）是DNA双链断裂（DSB）修复的两条主要通路。HR是一种精确的DSB修复机制，但仅限于S和G2期进行。相比之下，NHEJ在整个细胞周期中发挥作用，包括G1期。我们探讨了分别抑制G2/M检查点激酶PLK1或WEE1是否能够破坏有丝分裂控制，并暴露BRCA-WT/HR功能完备HGSOC细胞中的治疗脆弱性。我们在BRCA-WT/HR功能完备型和BRCA突变/HR缺陷型HGSOC模型中，评估了利用volasertib（选择性PLK1抑制剂）或adavosertib（高效WEE1抑制剂）来克服HR功能完备型化疗耐药的细胞周期靶向策略。两种药物均可诱导DNA损伤，削弱HR修复能力（降低RAD51焦点形成），并在BRCA-WT细胞中触发有丝分裂灾难——一种由有丝分裂缺陷和未修复DNA损伤导致的细胞死亡形式。Volasertib导致多倍体和异常纺锤体形成，提示发生有丝分裂滑移和胞质分裂失败；而adavosertib则消除了G2/M检查点，迫使细胞过早进入有丝分裂。相反，BRCA突变细胞对volasertib或adavosertib均表现出耐药性，这与其持续且功能完备的NHEJ活性一致。这种耐药性可通过药理或基因抑制DNA-PKcs（DNA依赖性蛋白激酶催化亚基，NHEJ的关键组分）来逆转。功能性和异种移植模型验证了BRCA-WT肿瘤对PLK1或WEE1抑制的选择性脆弱性。我们的研究揭示了细胞周期检查点抑制与DNA修复通路选择性之间的机制联系，为靶向HR功能完备性卵巢癌中的有丝分裂调控因子提供了理论依据——这是一个具有高度临床未被满足需求的亚群。

### 第二部分 AI 大师评价

本研究聚焦于BRCA1/2野生型且同源重组功能完备的高级别浆液性卵巢癌，探讨了抑制G2/M检查点激酶PLK1或WEE1对细胞周期与DNA修复互作的影响。作者采用药理学和基因学手段，在体内外模型中系统验证了这两种抑制剂在BRCA-WT细胞中的选择性杀伤作用。研究揭示了通过破坏有丝分裂控制来削弱HR修复的机制，并确认了NHEJ途径在耐药性中的关键作用。此发现为HR功能完备型卵巢癌的精准治疗提供了新的思路和潜在靶点，但具体的临床可行性尚需进一步验证。

---

## 26. RBM8A通过维持EGFR mRNA稳定性赋予胃癌奥沙利铂耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354714)
**期刊：** Oncogene
**PMID：** 41354714
**DOI：** 10.1038/s41388-025-03655-y

### 第一部分 原文与翻译

**英文原标题：** RBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability.

> **英文摘要：**
> RNA-binding proteins (RBPs) critically regulate post-transcriptional gene expression, yet their roles in chemotherapy resistance remain underexplored. Here, through a targeted siRNA screen of 40 RBM family members, we identified RNA-binding motif protein 8 A (RBM8A) as central orchestrator of oxaliplatin-induced DNA damage in gastric cancer (GC). Functional studies demonstrated that RBM8A promotes tumor proliferation and chemoresistance by recruiting the RNA helicase eIF4A3 to stabilize epidermal growth factor receptor (EGFR) mRNA, shielding it from exonucleolytic degradation. This stabilization sustains EGFR protein levels, enabling nuclear EGFR-DNA-PKcs complex formation to drive non-homologous end joining (NHEJ)-mediated DNA repair and suppress oxaliplatin-induced apoptosis. Therapeutic targeting of this axis with the EGFR inhibitor gefitinib restored oxaliplatin sensitivity in vitro and synergistically suppressed RBM8A-driven xenograft growth in vivo. Additionally, single-cell RNA-seq revealed RBM8A enrichment in malignant gastric epithelial cells, while tissue microarrays confirmed that dual RBM8A/EGFR overexpression predicts the poorest survival outcomes. Collectively, our findings define the RBM8A-eIF4A3-EGFR axis as a druggable determinant of chemoresistance and establish RBM8A as both a prognostic biomarker and therapeutic target in GC.

> **中文摘要：**
> RNA结合蛋白（RBPs）在转录后基因表达的调控中起关键作用，但其在化疗耐药中的作用仍鲜有研究。在本研究中，通过对40个RBM家族成员进行靶向siRNA筛选，我们确定了RNA结合基序蛋白8A（RBM8A）在胃癌（GC）中作为奥沙利铂诱导DNA损伤的核心调节因子。功能研究表明，RBM8A通过招募RNA解旋酶eIF4A3稳定表皮生长因子受体（EGFR）mRNA，从而保护其免受外切核酸酶降解，促进肿瘤增殖和化疗耐药性。该稳定作用维持了EGFR蛋白水平，使核内EGFR-DNA-PKcs复合物形成，进而驱动非同源末端连接（NHEJ）介导的DNA修复并抑制奥沙利铂诱导的细胞凋亡。通过EGFR抑制剂吉非替尼靶向阻断该信号轴，可在体外恢复奥沙利铂敏感性，并在体内协同抑制RBM8A驱动的异种移植瘤生长。此外，单细胞RNA测序显示RBM8A在恶性胃上皮细胞中富集，而组织芯片分析证实RBM8A与EGFR的高共表达预示患者最差的生存结局。综合而言，本研究揭示了RBM8A-eIF4A3-EGFR信号轴是可药靶向的化疗耐药决定因子，并确立RBM8A作为胃癌预后生物标志物和治疗靶点的潜在价值。

### 第二部分 AI 大师评价

该研究系统揭示了RBM8A在胃癌奥沙利铂耐药形成中的分子机制，证明其通过招募eIF4A3稳定EGFR mRNA来维持EGFR信号通路激活，从而促进DNA修复并抑制细胞凋亡。利用吉非替尼靶向阻断这一通路显著增强化疗敏感性，体现出较强的转化潜力。方法上结合siRNA筛选、功能实验及单细胞转录组与组织芯片分析，验证体系全面。创新性在于明确了可药靶向的RBM8A-eIF4A3-EGFR轴，但其临床应用仍需进一步验证。

---

## 27. 组织驻留微生物群影响结直肠癌的进展与预后

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354681)
**期刊：** Nature communications
**PMID：** 41354681
**DOI：** 10.1038/s41467-025-67047-2

### 第一部分 原文与翻译

**英文原标题：** Tissue-resident microbiota impacts colorectal cancer progression and prognosis.

> **英文摘要：**
> To deepen the understanding of tissue-resident microbiota in colorectal cancer (CRC), we analyzed whole-genome and transcriptome data from 937 patients. We identified 249 genera and 361 species commonly present in both tumors and adjacent normal tissues (NATs). Distinct microbial signatures were associated with anatomical location, tumor stages, hypermutation status, mutations in CRC driver and DNA damage repair genes, as well as consensus molecular subtypes (CMSs). Notably, the presence of the pks island and elevated abundance of Enterobacteriaceae were linked to poor prognosis specifically in CMS2 tumors. Finally, microbial risk scores derived from taxa present in tumor or NATs predicted patient prognosis independently of established clinico-molecular factors. Prognostic taxa were strongly associated with tumor transcriptomic pathways related to hypoxia, immune response, and metabolic status. These findings revealed the heterogeneity of tissue-resident microbiota and their critical role in CRC progression, highlighting potential avenues for targeted intervention.

> **中文摘要：**
> 为加深对结直肠癌（CRC）中组织驻留微生物群的理解，我们分析了来自937名患者的全基因组和转录组数据。我们鉴定出249个属和361个物种，它们在肿瘤及相邻正常组织（NATs）中普遍存在。不同的微生物特征与解剖部位、肿瘤分期、高突变状态、CRC驱动基因及DNA损伤修复基因突变，以及一致的分子亚型（CMSs）显著相关。值得注意的是，pks岛的存在以及肠杆菌科数量的升高，特异性地与CMS2型肿瘤的不良预后有关。最后，从肿瘤或NATs中存在的分类单元推导出的微生物风险评分，可以在既有临床分子因素之外独立预测患者预后。预后相关的分类单元与低氧、免疫应答及代谢状态相关的肿瘤转录组通路密切相关。这些发现揭示了组织驻留微生物群的异质性及其在CRC进展中的关键作用，强调了潜在的靶向干预方向。

### 第二部分 AI 大师评价

本研究旨在全面解析结直肠癌中组织驻留微生物群的组成及其与疾病进展和预后的关联。作者结合937例患者的全基因组与转录组信息，揭示了微生物群落在肿瘤与正常组织间的共性与差异性，并发现特定微生物特征与分子亚型及预后密切相关。特别是pks岛和肠杆菌科的富集与CMS2型肿瘤的不良结局关联显著。该研究在多组学整合分析和微生态预后模型方面具有显著创新性，但仍需进一步研究以验证微生物因果机制和临床应用价值。

---

## 28. 原核生物免疫中双酶反转元系统的结构与机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354673)
**期刊：** Nature communications
**PMID：** 41354673
**DOI：** 10.1038/s41467-025-67175-9

### 第一部分 原文与翻译

**英文原标题：** Architecture and mechanism of a dual-enzyme retron system in prokaryotic immunity.

> **英文摘要：**
> Retrons are bacterial genetic retroelements encoding a reverse transcriptase (RT) and a non-coding RNA (ncRNA)-multi-copy single-stranded DNA (msDNA) hybrid. Diverse effector proteins or domains are found to associate with retrons, typically forming tripartite toxin-antitoxin systems involved in anti-phage defense. Although retrons have attracted growing interest in genome editing technologies, the mechanisms underlying most retron-mediated immune systems remain poorly understood. Here, we characterize a distinct quaternary retron system, Ec78, harboring a dual-component effector complex in which the PtuA ATPase and PtuB nuclease act in concert to mediate phage clearance. The cryo-EM structure of the Ec78 complex adopts a flower-basket-like architecture, with two Ec78 retrons engaging the PtuAB effector complexes through a msDNA-insertion assembly mechanism. Shortening of msDNA in length releases the PtuAB from Ec78 retron and triggers its activation. The cryo-EM structure of the retron-unbound effector complex further reveals an arginine-lysine finger loop on the PtuB nuclease that undergoes an ordered-to-disordered transition during enzymatic activation. These findings delineate the molecular basis underlying the Ec78 system in antiviral defense and highlight the mechanistic diversity of retron systems in prokaryotic immunity.

> **中文摘要：**
> 反转元（retron）是一类细菌遗传逆转录元件，编码逆转录酶（RT）以及一种由非编码RNA（ncRNA）与多拷贝单链DNA（msDNA）组成的杂合体。研究发现，多种效应蛋白或结构域可与反转元相关联，通常形成参与抗噬菌体防御的三元毒素–抗毒素系统。尽管反转元在基因组编辑技术中受到越来越多的关注，但大多数反转元介导的免疫系统机制仍知之甚少。在本研究中，我们解析了一种独特的四元反转元系统 Ec78，其中包含一个双组分效应复合物，PtuA ATP酶与 PtuB 核酸酶协同作用以实现噬菌体清除。Ec78复合物的冷冻电镜结构呈现花篮状构架，其通过msDNA插入组装机制，使两个Ec78反转元与PtuAB效应复合物结合。缩短msDNA的长度可使PtuAB从Ec78反转元中释放，从而触发其活化。未结合反转元的效应复合物的冷冻电镜结构进一步揭示，PtuB核酸酶上的精氨酸–赖氨酸手指环在酶活化过程中经历由有序到无序的构象转变。这些发现阐明了Ec78系统在抗病毒防御中的分子基础，并突出了反转元系统在原核生物免疫中的机制多样性。

### 第二部分 AI 大师评价

该研究系统解析了原核生物反转元Ec78的结构与功能，揭示了PtuA ATP酶与PtuB核酸酶协同介导噬菌体清除的分子机制。通过冷冻电镜技术，作者发现Ec78复合物具有独特的花篮状结构，并揭示了msDNA长度对效应复合物活化的调控作用。研究进一步发现PtuB核酸酶在活化过程中的关键构象变化，为理解反转元系统的抗病毒防御机制提供了分子层面证据。该工作深化了对反转元系统多样性与功能调控的认知，对未来基于反转元的生物技术应用具有启示意义。

---

## 29. EP300缺失通过复制叉保护缺陷介导的慢性复制应激。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354653)
**期刊：** Nature communications
**PMID：** 41354653
**DOI：** 10.1038/s41467-025-67171-z

### 第一部分 原文与翻译

**英文原标题：** EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.

> **英文摘要：**
> Mutations in the global transcriptional activator EP300/KAT3B are being reported in aggressive malignancies. However, the mechanistic contribution of EP300 dysregulation to cancer is currently unknown. While EP300 has been implicated in regulating cell cycle and DNA replication, the role of EP300 in maintaining replication fork integrity has not been studied. Here, using EP300-mutated adult T-cell leukemia/lymphoma cells and an EP300-selective degrader, we reveal that EP300 loss leads to pronounced dysregulations in DNA replication dynamics and persistent genomic instability. Aberrant DNA replication in EP300-mutated cells is characterized by elevated replication origin firing due to replisome pausing. EP300 deficiency results in a prominent defect in fork protection resulting in the accumulation of single-stranded DNA gaps. Importantly, we find that the loss of EP300 results in decreased expression of BRCA2 protein leading to sensitivity to treatments that are cytotoxic to BRCA-deficient cancers. Overall, we demonstrate that EP300-mutated cells recapitulate features of BRCA-deficient cancers.

> **中文摘要：**
> 全局转录激活因子EP300/KAT3B的突变已在侵袭性恶性肿瘤中被报道。然而，EP300失调对癌症的机制性贡献目前尚不清楚。虽然EP300已被认为参与细胞周期和DNA复制的调控，但其在维持复制叉完整性方面的作用尚未得到研究。在本研究中，利用带有EP300突变的成人T细胞白血病/淋巴瘤细胞以及EP300特异性降解剂，我们发现EP300缺失导致DNA复制动力学发生显著紊乱，并引起持续的基因组不稳定。EP300突变细胞中的异常DNA复制表现为由于复制体停滞而导致的复制起点点火增加。EP300缺陷引起复制叉保护的显著缺失，从而导致单链DNA间隙的积累。重要的是，我们发现EP300丢失使BRCA2蛋白的表达减少，从而使细胞对对BRCA缺陷癌症具有细胞毒性的治疗更为敏感。总体而言，我们证明EP300突变细胞重现了BRCA缺陷癌症的特征。

### 第二部分 AI 大师评价

该研究旨在阐明EP300在维持DNA复制叉完整性及基因组稳定性中的功能机制。作者通过EP300突变T细胞白血病模型和化学降解实验，揭示EP300缺失会导致复制叉保护障碍和DNA单链间隙积累。研究进一步发现EP300缺失降低了BRCA2的表达，使细胞呈现出BRCA缺陷型癌症的典型脆弱性。该发现为理解EP300突变癌症的复制应激特征及药物敏感性提供了新的分子依据，但其在不同癌种中的普适性仍需进一步验证。

---

## 30. 高复制性丙型肝炎病毒变异株在免疫抑制患者中出现并导致严重疾病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354652)
**期刊：** Nature communications
**PMID：** 41354652
**DOI：** 10.1038/s41467-025-67174-w

### 第一部分 原文与翻译

**英文原标题：** Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease.

> **英文摘要：**
> Hepatitis C virus (HCV) exists as a heterogenous quasispecies, but the phenotypic consequences of viral variability are widely unexplored. Here we identify a replication enhancing domain (ReED) in non-structural protein 5A conferring high replication fitness to clinical isolates. Accumulation of mutations in the ReED mediates high genome replication capacity. In a cohort of liver transplant patients, high replicator variants are exclusively found in individuals with severe disease outcome, suggesting that high viral replication fitness is associated with increased viral pathogenesis. Analysis of large sequence cohorts reveals that overall only 10% of viral genomes show genetic signatures of high replicators, which are enriched in recipients of liver transplantations, patients developing hepatocellular carcinoma and in HIV coinfected individuals. Overall, our data suggests that low replication fitness is a hallmark of HCV, contributing to establishment of persistence, whereas high replicators appear to have an advantage under conditions of immune suppression, thereby enforcing pathogenesis.

> **中文摘要：**
> 丙型肝炎病毒（HCV）以异质性的准种形式存在，但其病毒变异所导致的表型后果仍然广泛未被探索。在本研究中，我们鉴定出位于非结构蛋白5A中的一个复制增强结构域（ReED），该结构域赋予临床分离株较高的复制适应性。ReED中突变的积累介导了显著增强的基因组复制能力。在一组肝移植患者中，仅在病情严重的个体中检测到高复制型变异株，提示高病毒复制适应性与增强的病毒致病性相关。对大型序列队列的分析显示，整体上仅约10%的病毒基因组表现出高复制型的遗传特征，这些特征在肝移植受者、发生肝细胞癌的患者及HIV共感染者中富集。总体而言，我们的数据表明，低复制适应性是HCV的一个特征，有助于病毒的持续存在，而高复制型病毒在免疫抑制状态下具有优势，从而强化了疾病的致病进程。

### 第二部分 AI 大师评价

该研究揭示了丙型肝炎病毒在免疫抑制背景下出现高复制型变异株，并阐明了非结构蛋白5A中复制增强结构域在病毒复制适应性中的关键作用。研究通过临床样本及大规模序列分析，将病毒复制能力与疾病严重程度建立关联，为理解HCV致病性提供了新的分子基础。其创新点在于定义了高复制型病毒的遗传标志及其临床分布特征。局限性在于需要进一步阐明该结构域突变对病毒生命周期其他环节的影响以及其在不同宿主背景中的稳定性。

---

## 31. 全基因组CRISPR筛选揭示PIK3CA抑制可增强脂质纳米颗粒介导的siRNA递送

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354630)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41354630
**DOI：** 10.1002/advs.202517617

### 第一部分 原文与翻译

**英文原标题：** Genome-Wide CRISPR Screen Reveals PIK3CA Inhibition Enhances Lipid Nanoparticle-Mediated siRNA Delivery.

> **英文摘要：**
> Lipid nanoparticles (LNPs) are useful carriers for therapeutic siRNA delivery, yet their clinical efficacy remains constrained by insufficient cellular uptake. Here, using a genome-wide CRISPR knockout screen, multiple genetic modulators of LNP uptake is uncovered, with PIK3CA emerging as a top druggable target. Pharmacologic inhibition of PIK3CA with BAY1082439 - a clinically evaluated small molecule - significantly enhances LNP uptake, siRNA delivery, and gene silencing across diverse epithelial cancer cell lines in vitro. Co-administration of BAY1082439 with siRNA-loaded LNPs also better suppressed tumor growth and reduced liver inflammation in vivo, respectively. These findings establish PIK3CA inhibition as a broadly applicable strategy to boost LNP-mediated RNA interference and highlight the promise of combining functional genomics with nanomaterials to advance RNA-based therapeutics.

> **中文摘要：**
> 脂质纳米颗粒（LNPs）是治疗性siRNA递送的有用载体，但其临床疗效仍受限于细胞摄取不足。本研究利用全基因组CRISPR敲除筛选，发现了多种调控LNP摄取的基因因素，其中PIK3CA成为最具药物开发潜力的靶点。使用经临床评估的小分子药物BAY1082439对PIK3CA进行药理性抑制，可显著提高LNP的摄取效率、siRNA递送水平及基因沉默效果，且在多种上皮性癌细胞系中均表现出一致性。在体内实验中，BAY1082439与负载siRNA的LNP联合给药可更有效地抑制肿瘤生长并减轻肝脏炎症。这些发现确立了PIK3CA抑制作为一种普适策略，可增强LNP介导的RNA干扰效应，并展示了结合功能基因组学与纳米材料以推动RNA类治疗的潜力。

### 第二部分 AI 大师评价

本研究通过全基因组CRISPR筛选系统性鉴定了调控脂质纳米颗粒递送效率的关键基因，突出揭示PIK3CA作为可药物化靶点的重要性。研究表明，PIK3CA抑制剂BAY1082439能够显著增强siRNA递送与基因沉默效应，并在体内表现出优越的抗肿瘤及抗炎作用。该工作将功能基因组学与纳米药物递送策略有机结合，为RNA治疗的精准化与高效化提供了新思路。其创新性在于从系统层面挖掘影响递送效率的分子通路，但仍需进一步验证其长期安全性与跨组织适用性。

---

## 32. 在 sgP19/kRAS 驱动的自发性转移性肝肿瘤模型中分离转移与上皮-间质转化的关系。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354626)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41354626
**DOI：** 10.1002/advs.202514198

### 第一部分 原文与翻译

**英文原标题：** Uncoupling Metastasis and Epithelial-to-Mesenchymal Transition in sgP19/kRAS-Driven Spontaneous Metastatic Liver Tumor Model.

> **英文摘要：**
> Epithelial-to-mesenchymal transition (EMT) is an early event during tumor metastasis. Here, the relevance of EMT in liver carcinogenesis and metastasis is sought to be determined in a murine mixed typical intrahepatic cholangiocarcinoma (iCCA)/sarcomatoid iCCA liver tumor model using CRISPR/Cas9-based gene deletion of p19 (sgP19) in combination with transposon-based expression of the activated form of pCaggs-kRAS (kRAS) in the mouse liver (sgP19/kRAS mixed model). It discovered that metastasis in the lymph node, lung, or kidney occurred in the sgP19/kRAS mixed model. Both typical iCCA tumor cells with epithelial features and sarcomatoid tumor cells with mesenchymal features could be detected in this model. Lineage tracing technology is applied to confirm the metastasis induced in the sgP19/kRAS model. Subsequently, the gain of expression of mesenchymal marker vimentin in tumor cells revealed the induction of EMT in the sgP19/kRAS model, and it is induced by activating the TGFβ/ZEB1 signaling pathway. Altogether, the study suggests that TGFβ/ZEB1 mediates the induction of EMT in iCCA, while targeting EMT failed to inhibit iCCA development or tumor metastasis, disputing the claims that EMT is a major molecular event leading to tumor metastasis.

> **中文摘要：**
> 上皮-间质转化（EMT）是肿瘤转移过程中早期发生的事件。本研究旨在通过利用 CRISPR/Cas9 技术在小鼠肝脏中敲除 p19 基因（sgP19），并结合转座子介导的活化型 pCaggs-kRAS（kRAS）的表达，构建一种混合型典型肝内胆管癌（iCCA）/肉瘤样 iCCA 肝肿瘤模型（sgP19/kRAS 混合模型），以评估 EMT 在肝癌发生与转移中的作用。研究发现，在 sgP19/kRAS 混合模型中可见淋巴结、肺或肾脏的转移灶。在此模型中，可检测到既具有上皮特征的典型 iCCA 肿瘤细胞，也存在具有间质特征的肉瘤样肿瘤细胞。研究应用谱系追踪技术确认 sgP19/kRAS 模型引起的转移。随后，肿瘤细胞中间质标志物波形蛋白（vimentin）的表达增强，提示该模型中诱导了 EMT，而此过程由 TGFβ/ZEB1 信号通路激活所介导。总体而言，该研究表明 TGFβ/ZEB1 介导了 iCCA 中 EMT 的诱导，但针对 EMT 的抑制未能阻止 iCCA 的发生或肿瘤转移，从而质疑了“EMT 是导致肿瘤转移的主要分子事件”这一传统观点。

### 第二部分 AI 大师评价

本研究在小鼠 sgP19/kRAS 驱动的肝内胆管癌模型中系统探讨了 EMT 与肿瘤转移的关系。通过结合 CRISPR/Cas9 基因编辑和转座子系统，作者构建了具有上皮型与间质型细胞并存的混合型肝肿瘤模型，并利用谱系追踪和蛋白标志物分析揭示 TGFβ/ZEB1 通路在诱导 EMT 中的作用。结果显示，尽管 EMT 发生，但抑制 EMT 并不能阻止肿瘤的发生与转移，提示 EMT 不是转移必需事件。该研究为重新审视 EMT 在肿瘤进展中的地位提供了重要实验依据，但模型特异性及转化意义仍需进一步验证。

---

## 33. 多组学揭示膝关节滑膜炎中失调的肠–关节轴：来自中国两项骨关节炎研究的数据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354462)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41354462
**DOI：** 10.1002/advs.202512020

### 第一部分 原文与翻译

**英文原标题：** Multi-Omics Reveal the Dysregulated Gut-Joint Axis in Knee Synovitis: Data from Two Osteoarthritis Studies in China.

> **英文摘要：**
> Gut microbiota dysbiosis and associated host immuno-metabolic disorders may play a role in knee synovitis. Herein, integrated multi-omics analyses of stool and blood samples from subjects from Pearl River Osteoarthritis Cohort (PROC, N = 207) are conducted to explore the potential gut-joint axis. Specifically, gut metagenomics, serum metabolomics and plasma proteomics are carried out. Knee synovitis is identified by magnetic resonance imaging. A total of 87 synovitis cases are identified in PROC, which are characterized by increased Firmicutes/Bacteroidetes (F/B) ratio. Alterations in microbial functions of both leucine and geraniol degradation are closely associated with increased serum 3-hydroxyisovaleric acid and decreased geranic acid. These perturbations are significantly correlated with F/B ratio and down-regulated plasma TWEAK. Building upon these, the potential synovial targets are explored using a synovial single-cell dataset and the Nanjing Osteoarthritis Cohort (NOC, N = 22). Synovial fluid proteomics, histological analysis, and in vitro experiments with human fibroblast-like synoviocytes (FLS) are conducted for NOC subjects with different synovitis grades. An upregulated TWEAK receptor is found in higher grade of synovitis. In vitro, higher TWEAK induced down-regulated TWEAK receptor in FLS. The study for the first time revealed the gut-joint axis in knee synovitis, providing new insight into potential targets for synovitis treatment.

> **中文摘要：**
> 肠道菌群失调及其相关的宿主免疫代谢紊乱可能在膝关节滑膜炎中发挥作用。本研究对来自珠江骨关节炎队列（PROC，N = 207）受试者的粪便和血液样本进行了综合多组学分析，以探索潜在的肠–关节轴。具体而言，研究实施了肠道宏基因组学、血清代谢组学和血浆蛋白质组学分析。膝关节滑膜炎通过磁共振成像确诊。在 PROC 中共发现 87 例滑膜炎病例，其特征为厚壁菌门/拟杆菌门（F/B）比例增高。亮氨酸和香叶醇分解功能的微生物学改变量与血清中 3-羟基异戊酸升高及香叶酸降低密切相关。这些扰动与 F/B 比例及血浆中 TWEAK 下调显著相关。在此基础上，研究利用滑膜单细胞数据集及南京骨关节炎队列（NOC，N = 22）探索潜在的滑膜靶点。针对 NOC 不同滑膜炎分级的受试者，进行了滑液蛋白质组学、组织学分析及人滑膜成纤维样细胞（FLS）的体外实验。在高级别滑膜炎中发现 TWEAK 受体上调，而在体外条件下，较高水平的 TWEAK 可诱导 FLS 中 TWEAK 受体下调。本研究首次揭示了膝关节滑膜炎中的肠–关节轴，为滑膜炎的治疗提供了新的潜在靶点与见解。

### 第二部分 AI 大师评价

本研究通过整合肠道宏基因组学、血清代谢组学和血浆蛋白质组学，系统揭示了膝关节滑膜炎中肠–关节轴的分子失调。研究发现肠道菌群结构、代谢产物与系统性炎症信号（尤其是 TWEAK 轴）存在显著关联，并进一步通过单细胞数据和体外实验验证了滑膜水平的作用机制。该工作在机制层面创新性地连接了肠道微生物失衡与关节炎性病变，为靶向滑膜炎的干预提出了新方向。其局限在于队列规模相对有限及因果关系尚需纵向与干预性研究验证。

---

## 34. Pirtobrutinib 与 Ibrutinib 在初治及复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353787)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41353787
**DOI：** 10.1200/JCO-25-02477

### 第一部分 原文与翻译

**英文原标题：** Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

> **英文摘要：**
> PURPOSE: Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease.
> 
> PATIENTS AND METHODS: Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients with RR disease.
> 
> RESULTS: The study met its primary end points, demonstrating statistically significant noninferiority (NI) of IRC-ORR for pirtobrutinib versus ibrutinib in both the ITT (87.0% [95% CI, 82.9 to 90.4]  78.5% [95% CI, 73.7 to 82.9]; ORR ratio = 1.11 [95% CI, 1.03 to 1.19]; two-sided  < .0001) and R/R populations (n = 437; 84.0% [95% CI, 78.5 to 88.6]  74.8% [95% CI, 68.5 to 80.4]; ORR ratio = 1.12 [95% CI, 1.02 to 1.24]; two-sided  < .0001). In TN patients (n = 225), IRC-ORR was 92.9% (95% CI, 86.4 to 96.9) with pirtobrutinib versus 85.8% (95% CI, 78.0 to 91.7) with ibrutinib. Investigator assessed ORR results were consistent. Investigator-assessed progression-free survival (PFS) favored pirtobrutinib in the ITT (hazard ratio [HR], 0.57 [95% CI, 0.39 to 0.83]), R/R (HR, 0.73 [95% CI, 0.47 to 1.13]), and TN (HR, 0.24 [95% CI, 0.10 to 0.59]) populations. Cardiac adverse event rates of atrial fibrillation/flutter and hypertension were lower with pirtobrutinib.
> 
> CONCLUSION: Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.

> **中文摘要：**
> 研究目的：Pirtobrutinib 是一种高度选择性的非共价型布鲁顿酪氨酸激酶抑制剂（BTKi），在既往接受过共价型 BTKi 治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者中已显示出疗效和安全性。本研究报道了（据我们所知）首个在 BTKi 初治的 CLL/SLL 患者中，对比 pirtobrutinib 与 ibrutinib 的随机、正面对照试验结果，研究对象包括初治（TN）和复发/难治性（R/R）两类患者。
> 
> 患者与方法：共纳入患者 662 例，按 1:1 比例随机分配接受 pirtobrutinib 或 ibrutinib，所有入组患者均为 BTKi 初治。主要终点包括独立评审委员会（IRC）评定的总体缓解率（ORR），分析对象为所有随机分组患者（意向治疗[ITT]人群）及 R/R 人群。
> 
> 结果：研究达到了主要终点，显示在 ITT 人群（87.0%［95% CI，82.9–90.4］ 对 78.5%［95% CI，73.7–82.9］；ORR 比值 = 1.11［95% CI，1.03–1.19］；双侧 P < .0001）和 R/R 人群（n = 437；84.0%［95% CI，78.5–88.6］ 对 74.8%［95% CI，68.5–80.4］；ORR 比值 = 1.12［95% CI，1.02–1.24］；双侧 P < .0001）中，pirtobrutinib 的 IRC-ORR 均达到统计学非劣效性（NI）。在 TN 患者（n = 225）中，pirtobrutinib 的 IRC-ORR 为 92.9%（95% CI，86.4–96.9），而 ibrutinib 为 85.8%（95% CI，78.0–91.7）。研究者评估的 ORR 结果一致。研究者评估的无进展生存期（PFS）在 ITT（风险比 [HR] 0.57［95% CI，0.39–0.83］）、R/R（HR 0.73［95% CI，0.47–1.13］）及 TN（HR 0.24［95% CI，0.10–0.59］）人群中均倾向于 pirtobrutinib 更为有利。心脏不良事件如房颤/房扑及高血压的发生率在 pirtobrutinib 组较低。
> 
> 结论：Pirtobrutinib 在总体缓解率方面相较于 ibrutinib 显示出非劣效性，并在早期无进展生存期方面表现出有利趋势，尤其是在初治患者中，同时具有更优的安全性特征，包括较低的房颤和高血压发生率。

### 第二部分 AI 大师评价

本研究为首次比较 pirtobrutinib 与 ibrutinib 的随机、正面对照试验，涵盖初治及复发/难治性 CLL/SLL 患者。结果显示，pirtobrutinib 在总体缓解率方面实现与 ibrutinib 的非劣效性，且在无进展生存期方面呈现出一定优势。其安全性更佳，尤其在心血管不良事件方面表现优越。研究验证了非共价型 BTKi 的潜在临床优势，为 CLL/SLL 的一线及复发治疗提供了新的选择。局限性在于随访时间尚短，长期结局仍需进一步观察。

---

## 35. 一种经验证的系统性AL淀粉样变新分期系统，其中IIIC期定义为极高风险：AL国际分期系统（AL-ISS）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353737)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41353737
**DOI：** 10.1200/JCO-25-02558

### 第一部分 原文与翻译

**英文原标题：** A new validated staging system for AL amyloidosis with Stage IIIC defining ultra-poor risk: AL International Staging System (AL-ISS).

> **英文摘要：**
> BACKGROUND: Outcomes in systemic AL amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-based (NT-proBNP and Troponin-T) staging system in the contemporary treatment era (2015-2024).
> 
> METHODS: AL International Staging System (AL-ISS) was derived from a cohort of patients with AL amyloidosis from the UK National Amyloidosis Centre (2015-2019). The model was validated in patient cohorts from Europe (Greece, Italy, Netherlands, Switzerland), USA (2015-2024) and UK (2020-2024).
> 
> RESULTS: 2493 patients were included (derivation, n=573; validation n=1920). In a multivariable model for the derivation cohort, LS≥-9% and cardiac biomarkers at previously validated thresholds (NT-proBNP 332 ng/L and 8500 ng/L and hs-TnT>50 ng/L) were independent poor prognostic factors stratifying patients into stages I, II, IIIA, IIIB and IIIC. In the validation cohort, the patient stages were stage I: 317 (17%), II: 782 (41%), IIIA: 551 (29%), IIIB: 174 (9%) and IIIC: 96 (5%), respectively (first-line daratumumab treated: 826; 43%). With a median follow-up of 34 months, median overall survival (OS) was not reached (NR); estimated 1-year, 2-year and 3-year OS was 82%, 74% and 70% respectively. Median survival for stages I-II, IIIA, IIIB and IIIC were NR, 67, 26 and 7 months (1-year OS IIIC 53% v 68% for IIIB in the daratumumab-treated patients), respectively (p<0.001). External validation exhibited good predictive performance: 12-month calibration slope was 1.09, Harrell's C 0.69, Royston's D 1.19, R 0.25. Stage IIIC independently discriminated the poorest outcome across all cohorts.
> 
> CONCLUSION: This defines and validates a new staging system from systemic AL amyloidosis with robust identification of an ultra-poor risk stage (IIIC) in contemporarily treated patients.

> **中文摘要：**
> 背景：随着现代疗法的应用，系统性AL淀粉样变患者的预后已显著改善，但现有风险分层模型的适用性受到限制。本研究验证了一种新的分期系统，在生物标志物（NT-proBNP和肌钙蛋白T）分期系统的基础上，加入纵向应变（LS），以适应2015至2024年的当代治疗时代。
> 
> 方法：AL国际分期系统（AL-ISS）基于英国国家淀粉样变中心2015至2019年收集的AL淀粉样变患者队列开发。该模型进一步在欧洲（希腊、意大利、荷兰、瑞士）、美国（2015–2024）及英国（2020–2024）的患者队列中进行了验证。
> 
> 结果：共纳入2493例患者（建模队列573例，验证队列1920例）。在多变量模型中，LS≥-9%以及心脏生物标志物达到已验证阈值（NT-proBNP 332 ng/L和8500 ng/L，hs-TnT>50 ng/L）均为独立的不良预后因素，可将患者区分为I、II、IIIA、IIIB和IIIC期。在验证队列中，各期患者分布为I期317例（17%）、II期782例（41%）、IIIA期551例（29%）、IIIB期174例（9%）、IIIC期96例（5%）；其中826例（43%）接受了第一线达雷妥尤单抗治疗。中位随访34个月，整体生存期（OS）中位值未达到；估算的1年、2年和3年OS分别为82%、74%和70%。I–II期、IIIA期、IIIB期和IIIC期的中位生存期分别为未达到、67个月、26个月和7个月；在达雷妥尤单抗治疗患者中，IIIC期1年OS为53%，而IIIB期为68%（p<0.001）。外部验证显示预测性能良好：12个月校准斜率1.09，Harrell's C为0.69，Royston’s D为1.19，R为0.25。IIIC期在所有队列中均能独立区分最差预后人群。
> 
> 结论：本研究定义并验证了一种新的系统性AL淀粉样变分期系统，能够在当代治疗条件下稳健识别极高风险的IIIC期患者。

### 第二部分 AI 大师评价

该研究旨在构建并验证一种新的系统性AL淀粉样变国际分期系统（AL-ISS），结合纵向应变与传统心脏生物标志物以优化风险分层。研究利用多国和多时间段的大规模患者数据进行模型建立与外部验证。结果显示，新系统能够区分不同风险层，尤其是定义了预后极差的IIIC期。该分期系统在预测性能上表现稳定，对临床风险评估和个体化治疗具有潜在应用价值。但仍需进一步在真实世界环境中验证其广泛适用性。

---

## 36. 利用冷冻保存组织构建的肺–免疫双人源化小鼠模型可实现人类普通感冒冠状病毒的感染与免疫特征分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353654)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41353654
**DOI：** 10.1002/advs.202512097

### 第一部分 原文与翻译

**英文原标题：** A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.

> **英文摘要：**
> Human common cold coronaviruses (CCCoVs, e.g., 229E, NL63, OC43, HKU1) hold critical yet underexplored significance in understanding coronavirus evolutionary dynamics and immune cross-protection, offering insights for predicting emerging pathogens and developing pan-coronavirus vaccines. However, research is hindered by the lack of animal models due to strict human-specific tropism and the confounding effects of frequent co-infections from clinical samples, which obscure virus-specific pathogenesis. Although lung-humanized mice have been used in SARS-CoV-2 studies, their application to CCCoVs remains unvalidated and relies on logistically challenging fresh human tissues. This study optimizes a transplantation strategy using cryopreserved human fetal lung tissue, achieving enhanced engraftment efficiency. And the refined model supports robust infection by all four major CCCoVs and demonstrates the therapeutic efficacy of Paxlovid against HKU1. Furthermore, comparative analysis reveals phenotypic distinctions in human immune cells between native mouse lungs and human lung implants in lung-immune dual-humanized mice. The model also enables validation of virus-specific T cell responses and assessment of SARS-CoV-2 cross-reactivity post-HKU1 infection. Overall, this study establishes a scalable platform using cryopreserved tissues for respiratory virus research, overcoming prior limitations in modeling human-specific tropism and dissecting immune-pathogen interactions.

> **中文摘要：**
> 人类普通感冒冠状病毒（CCCoVs，如229E、NL63、OC43、HKU1）在理解冠状病毒的进化动态和免疫交叉保护中具有关键但尚未充分研究的重要意义，为预测新发病原体和开发广谱冠状病毒疫苗提供了重要启示。然而，由于严格的人特异性嗜性以及临床样本中频繁的混合感染所带来的干扰，缺乏合适的动物模型阻碍了相关研究，这使得特定病毒的致病机制难以解析。尽管肺人源化小鼠已被用于SARS-CoV-2的研究，但其在CCCoVs中的应用尚未得到验证，并依赖于操作上极具挑战的新鲜人源组织。本研究通过优化一种利用冷冻保存的人类胎儿肺组织的移植策略，实现了增强的移植物成活效率。改进的模型能够支持四种主要CCCoVs的有效感染，并验证了Paxlovid对HKU1感染的治疗效果。此外，对比分析显示，在肺–免疫双人源化小鼠中，人源免疫细胞在原生小鼠肺与人源肺植入组织之间表现出表型差异。该模型还可用于验证病毒特异性T细胞反应，并在HKU1感染后评估其对SARS-CoV-2的交叉反应性。总体而言，本研究建立了一种基于冷冻保存组织的可扩展呼吸道病毒研究平台，克服了以往在人特异性嗜性建模和免疫–病原体相互作用解析方面的局限性。

### 第二部分 AI 大师评价

该研究旨在开发一种可重复且可扩展的肺–免疫双人源化小鼠模型，用于研究人类普通感冒冠状病毒的感染与免疫反应。研究创新性地利用冷冻保存的人类胎儿肺组织，提高了移植物成活率并实现多种CCCoVs的稳定感染。模型验证了Paxlovid对HKU1的抗病毒疗效，并揭示了人源免疫细胞在不同组织环境中的表型差异。该平台为探究人特异性呼吸道病毒的免疫机制及跨冠状病毒免疫反应提供了新的研究工具，但仍需进一步评估其长期免疫重建稳定性与临床可转化性。

---

速递结束，祝您工作愉快！